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ABSTRACT 
Approximately 20% of Canadian adults currently smoke, despite widespread 
knowledge of the significant health problems associated with tobacco use. Of the many 
smoking cessation interventions developed, contingency management (CM) appears to be 
among the most efficacious. This type of external motivation has previously been shown 
to be very efficacious when the contingency is in place, but its effects tend to diminish 
once the contingency is removed. In contrast, motivational interviewing (MI) is designed 
to increase an individual's internal motivation for behaviour change. Studies have shown 
this type of intervention to produce modest effects for smoking cessation, although 
follow-up data suggest that the effects of such interventions can be relatively long-
lasting. 
This study evaluated the combined efficacy of CM and a brief computer-delivered 
motivational intervention (CDMI) for smoking cessation. This CDMI is based on the 
principles of MI but is modified from this traditional approach in order to accommodate a 
computerized delivery of the intervention. The intention was to harness the short-term 
effectiveness of CM while enhancing or perhaps extending its effects by combining it 
with CDMI. Using a sample of 48 opiate-dependent persons receiving methadone 
maintenance therapy, this randomized trial compared rates of smoking cessation for 
patients receiving CDMI and CM together to those of patients receiving CDMI alone or 
treatment as usual. 
Results indicated that the combination of CDMI and CM was most effective at 
producing reductions in breath carbon monoxide during the four-week study period, 
while CDMI only participants endorsed the highest levels of motivation to quit smoking. 
V 
At five-week follow-up, CDMI only participants continued to show reductions in number 
of cigarettes smoked, while CDMI plus CM participants increased their use of cigarettes 
relative to when the intervention was in place. These results are discussed with respect to 
the Self-Determination Theory and are used to suggest directions for future research and 
larger scale studies. 
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Smoking is the most preventable cause of death and disease in the United States and 
Canada. Each year, tobacco is responsible for over 438,000 (or about one in five) deaths 
in the United States alone (Centers for Disease Control and Prevention, 2005). Although 
smoking prevalence rates have dropped over the past two decades, current estimates 
suggest that 20% of Canadians smoke cigarettes (Health Canada, 2006). 
There are a wide variety of interventions designed to reduce tobacco use. 
Systematic reviews support the efficacy of nicotine replacement therapy (Silagy, 
Lancaster, Stead, Mant, & Fowler, 2006), individual behavioural counselling (Lancaster 
& Stead, 2006a), treatment with the antidepressants bupropion and nortriptyline (Hughes, 
Stead, & Lancaster, 2006a), and especially varenicline (e.g., Jorenby et al., 2006). In each 
case, these interventions have been found to be 1.5 times more effective relative to no-
treatment groups. Less effective but still promising treatments include self-help materials 
(Lancaster & Stead, 2006b), quit and win contests (Hey & Perera, 2006a), and group 
therapy (Stead & Lancaster, 2006). There is currently very little evidence to support other 
interventions such as relapse prevention (Hajek, Stead, West, Jarvis, & Lancaster, 2006), 
exercise programs (Ussher, 2006), anxiolytics (Hughes, Stead, & Lancaster, 2006b), and 
acupuncture or laser therapy (White, Rampes, & Campbell, 2006). 
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Contingency Management 
Contingency management (CM) has been shown to have powerful short-term 
effects on smoking. CM provides an external motivation for behaviour change following 
the principles of behaviour therapy (itself a product of operant conditioning research). 
When the target behaviour (e.g., tobacco abstinence) is observed, the individual is 
reinforced, often with a token or voucher exchangeable for retail goods. When the 
behaviour is not observed, no reward is provided (Petry & Simcic, 2002). Although 
decades of research have demonstrated the efficacy of CM in treating substance abuse 
(Higgins & Silverman, 1999), CM is often criticized because the reinforced behaviours 
tend to diminish or extinguish when the contingency is removed (Petry, 2000). Reviews 
of this research confirm that these incentives enhance short-term cessation rates, but the 
gains tend to dissipate once the rewards are no longer available (Hey & Perera, 2006b; 
Prendergast, Podus, Finney, Greenwell, & Roll, 2006). 
Two recent meta-analyses suggest that CM for substance use produces moderate 
effect sizes, with one study reporting an average effect size of r = .32 (Lussier, Heil, 
Mongeon, Badger, & Higgins, 2006) and the second reporting an average effect of d = 
.42 (Prendergast et al., 2006). These effects were found to be larger when the delivery of 
the contingency was immediate, the monetary value of the contingency was high (Lussier 
et al., 2006), and the treatment duration was relatively brief (Prendergast et al., 2006). 
With respect to smoking cessation, CM appears to be remarkably efficacious as 
an intervention (e.g., Heil, Tidey, Holmes, Badger, & Higgins, 2003; Rand, Stitzer, 
Bigelow, & Mead, 1989; Stitzer & Bigelow, 1985). However, long-term follow-up data 
suggest that CM only delays relapse to smoking, and does not reduce smoking levels 
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relative to baseline (Rand et al., 1989). In general, results for CM are less durable than 
those for most approaches, as the CM intervention is most effective when the 
contingency is in place. 
Motivational interviewing 
Motivational interviewing (MI) has been shown to have more lasting effects on 
behaviour change. Broadly, MI is a client-centred counselling method designed to 
enhance an individual's motivation for behaviour change (Miller & Mount, 2001). This is 
done through reflective listening and a directive but non-confrontational approach. MI is 
typically a brief intervention that includes assessment of problem behaviours, 
personalized feedback, exploration of ambivalence regarding change, and elicitation of 
the patient's own reasons for possibly wanting to change (Miller & Rollnick, 1991). 
Several meta-analyses support a number of conclusions regarding MI. First, MI is 
effective at producing change across a wide variety of behaviours, ranging from diet and 
exercise to substance abuse. Although effect sizes vary, MI tends to produce moderate 
effects in the range of .35 to .56 relative to no-treatment comparisons (Burke, Dunn, 
Atkins, & Phelps, 2004). Second, MI often works as well as longer interventions (Burke 
et al., 2004). For example, in one meta-analysis, MI was found to be as efficacious as 
alternative treatments, despite being shorter than comparison treatments by an average of 
180 minutes (Burke, Arkowitz, & Menchola, 2003). Third, MI appears to be most 
effective when used as an enhancement to other treatments (Burke et al., 2003; Dunn, 
Deroo, & Rivara, 2001). Fourth, MI may be most effective with individuals who are more 
angry/resistant and less ready to change (Burke et al., 2004; Heather, Rollnick, Bell, & 
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Richmond, 1996; Project MATCH Research Group, 1997), and MI may be 
contraindicated for individuals who are already committed to behaviour change 
(Hettema, Steel, & Miller, 2005). There is also some evidence to suggest that the effects 
of MI are larger for minority samples (Hettema et al., 2005). 
With respect to follow-up data, MI appears to produce lasting effects. Dunn et al. 
(2001) found evidence to suggest that the effects of MI remain the same regardless of the 
length of time of the follow-up. Similarly, Burke et al. (2003) found that across several 
studies, the effect sizes at 20 weeks follow-up were not significantly different than effect 
sizes at 67 weeks follow-up. This is consistent with other meta-analytic reviews that have 
shown that brief MI for alcohol abuse can lead to reductions in drinking six to 12 months 
after the intervention (Wilk, Jensen, & Havighurst, 1997). 
MI targeting smoking cessation tends to produce smaller effects than MI targeting 
other substances of abuse. Recent meta-analyses estimate the effect size for such 
interventions, relative to a no treatment/placebo condition, to range from . 11 (Burke et 
al., 2003; Burke et al., 2004) to .14 (Hettema et al., 2005). However, these small effect 
sizes are comparable to those for most other smoking cessation interventions (Lancaster 
& Stead, 2006a), for which statistical significance is often only obtainable in very highly 
powered studies. The relatively weak effect of MI for smoking cessation may also be a 
result of the disordinal efficacy of MI noted earlier: MI may in fact be ineffective or even 
deleterious with many of the more highly motivated individuals who smoke, but quite 
efficacious with those less motivated. The strong effects of interventions using the 5 As 
approach (̂ 4sk about smoking status, Advise to quit smoking, Assess interest in quitting, 
Assist in quitting, Arrange Follow-up; e.g. Fiore et al., 2000; Pbert et al., 2004), which 
5 
presents motivational techniques to those less motivated and problem solving/goal setting 
to those with more motivation, supports this suggestion. 
Computerized interventions 
One innovative method of delivering interventions such as MI has been through 
computerized programs. Computerized interventions offer many advantages over 
traditional interventions, such as the limited time commitment required from health care 
providers, the minimal costs associated with their use, the ability of users to maintain 
their anonymity, and the intervention's potential accessibility (Copeland & Martin, 
2004). Because of this accessibility, these computerized approaches offer the possibility 
of reaching a large group of people regardless of their age, gender, or socio-economic 
status. This also includes individuals who may not otherwise receive support for their quit 
attempt or who may not have been considering reducing their substance use (Ondersma, 
Chase, Svikis, & Schuster, 2005). 
Computer-based interventions using such change strategies as psychoeducation, 
cognitive restructuring, relapse prevention, and behavioural self-control training have 
previously been developed. These interventions address a wide variety of mental health 
problems, such as depression and anxiety disorders (e.g., Carlbring, Westling, 
Ljungstrand, Ekselius, & Andersson, 2001; Christensen, Griffiths, & Korten, 2002; 
Lange, van de Ven, Schrieken, & Emmelkamp, 2001) as well as behavioural health 
problems such as obesity (Tate, Wing, & Winett, 2001). These computerized 
interventions have also been shown to be effective for reducing alcohol (Hester & 
Delaney, 1997), drug (Ondersma et al., 2005), and tobacco (Schneider, Walter, & 
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O'Donnell, 1990) use. One study has shown brief computerized interventions to reduce 
hazardous drinking at rates similar to practitioner-delivered interventions (Kypri et al., 
2004). 
Smoking and methadone maintenance 
Smoking rates are particularly high among substance abusers. Over 90% of 
individuals in inpatient treatment for alcohol dependence have been found to smoke 
cigarettes (Bien & Burge, 1990), and rates ranging from 74% to 88% have been reported 
for individuals in treatment for drug dependence (Kalman, 1998). In particular, opiate 
users in treatment have among the highest smoking rates in the US population (Stein & 
Anderson, 2003). Amongst methadone-maintained individuals, smoking prevalence rates 
of 85% to 100% have been reported (Best et al., 1998; Chait & Griffiths, 1984; 
Clemmey, Brooner, Chutuape, Kidorf, & Stitzer, 1997; Stark & Campbell, 1993). 
The most common and efficacious treatment for opiate dependence is methadone 
maintenance therapy. Methadone is a medication used for the past 40 years in the 
treatment of heroin addiction. It acts by occupying the opiate receptor and blocking the 
"high" that comes from heroin use. Methadone also eliminates withdrawal symptoms and 
craving for heroin (Zickler, 1999). In Canada, the number of individuals receiving 
methadone maintenance therapy is growing, with an almost five-fold increase in Ontario 
alone between 1996 and 2001 (Strike, Urbanoski, Fischer, Marsh, & Millson, 2005). The 
high rate of smoking prevalence, coupled with the daily dispensing of methadone, 
presents a unique opportunity for implementing smoking cessation programs with opiate-
dependent individuals in treatment. 
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Given the high rates of tobacco use in methadone-maintained individuals, several 
authors have suggested that more needs to be done to address smoking in this population 
(e.g., Olsen, Alford, Horton, & Saitz, 2005; Richter & Ahluwalia, 2000; Richter, Choi, 
McCool, Harris, & Ahluwalia, 2004). Despite this, relatively few smoking intervention 
studies have been designed for those in methadone treatment. Although a limited number 
of approaches have been studied to date, CM or MI have been included as interventions 
in each of these studies. 
Contingency management with methadone-maintained individuals 
A number of studies have utilized CM within methadone-maintained samples. In 
one example of a CM approach, 17 methadone-maintained smokers were followed over a 
four-week period (Shoptaw, Jarvik, Ling, & Rawson, 1996). As part of the CM, breath 
carbon monoxide (CO) was assessed three times a week. For each sample that indicated 
recent abstinence from smoking, participants were given vouchers that could be 
exchanged for merchandise at the end of the study. These vouchers increased in value for 
each consecutive day of smoking abstinence. During the CM period, breath CO levels 
were significantly reduced (indicating less smoking) relative to baseline. Almost one in 
four participants (23.4%) were able to maintain at least one week of continuous smoking 
abstinence. Although these results appear promising, all patients had resumed smoking 
by the end of the study. Breath CO levels did suggest, however, that they had reduced 
their cigarette smoking relative to baseline. 
Researchers have also studied the effects of CM as part of more comprehensive 
smoking cessation programs. This line of study shows some support for its short-term 
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effectiveness above and beyond other approaches. Shoptaw et al. (2002) compared the 
efficacy of relapse prevention and CM (alone and in combination) for individuals 
receiving nicotine replacement therapy. A total of 175 methadone-maintained individuals 
were placed into one of four conditions: 1) nicotine replacement therapy only (control 
condition); 2) relapse prevention and nicotine replacement therapy; 3) CM and nicotine 
replacement therapy; and 4) relapse prevention, CM, and nicotine replacement therapy. 
During the 12-week study period, participants provided thrice weekly samples of breath 
CO, urine (tested for opiate and cocaine use), and self-reports on the number of cigarettes 
smoked. Participants were found to provide more opiate- and cocaine-free urines on the 
weeks that they met criteria for smoking abstinence. In terms of the effectiveness of the 
intervention on smoking, participants who received CM showed higher rates of smoking 
abstinence during the study period. No effect was found for those receiving relapse 
prevention alone. However, the gains made by the CM groups were not maintained at six-
and 12- month follow-up. 
Therefore, just as with CM interventions for smoking cessation in the general 
population, CM with methadone maintained individuals appears to result in significant 
but short-lasting reductions in smoking behaviour. 
Motivational interviewing with methadone-maintained individuals 
Only one smoking intervention study using MI with methadone maintained 
individuals has been found. Haug, Svikis, and DiClemente (2004) studied 63 pregnant, 
methadone-maintained smokers. All participants received smoking cessation advice from 
health practitioners, as well as printed material regarding the harmful effects of smoking 
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during pregnancy. Half of the women also received four individual sessions of MI. At 
ten-week follow-up, no difference in smoking (via self-report, urine cotinine, or breath 
CO) was found between the MI group and the standard care group. However, women 
who received the MI were more likely to have increased their motivation to change, 
while the standard care group endorsed less motivation relative to the start of the study 
period. 
Other research suggests that methadone-maintained individuals respond well to 
motivational strategies when the intervention targets opiate use (Saunders, Wilkinson, & 
Phillips, 1995). A total of 57 methadone maintained patients received one hour of MI 
regarding their opiate use. They were compared to a group (N= 65) that received an 
educational procedure (consisting of a presentation and discussion) on the physical 
effects of opiate use, brief advice on how to stop, and referral information. At the six-
month follow-up, those who received the MI showed greater commitment to opiate 
abstinence and fewer opiate-related problems. The MI group also remained in methadone 
treatment longer, and for those who did relapse to opiates, it took them longer to relapse 
than the educational group. Saunders et al. (1995) found that after just one hour of MI, 
lasting effects on opiate use could be seen six months later. This supports a recent 
systematic review that suggests that brief interventions for smoking are just as effective 
as more intensive counselling methods (Lancaster & Stead, 2006a). 
There is therefore some indication that MI with methadone-maintained 
individuals leads to longer-term gains relative to standard care or educational 
interventions. These effects may be seen after even very brief interventions. 
10 
First research objective: Combined intervention effects 
This study intends to build on this previous research in several ways. First, it 
examines the efficacy of a combined intervention that aims to increase internal 
motivation (via a brief computer-delivered motivational-based intervention [CDMI]) 
while also building external motivation (via CM). The intent is to harness CM's powerful 
short-term effects while also engaging the potentially longer-term effects of the CDMI. 
This CDMI is based on the principles of MI, and is superficially very much like a 
typical MI session. However, MI by definition is a highly empathic interpersonal process; 
the CDMI thus cannot be properly understood as MI. It is more accurate to say that it is a 
motivational intervention. 
Theory behind combined interventions 
Self-determination theory (SDT; Deci & Ryan, 1985) is helpful in guiding 
hypotheses for this combined intervention group. SDT is a theory of motivation that 
addresses the degree to which human behaviours are self-determined and involve free 
choice. This theory developed in part out of the investigation of the effects of external 
rewards on internal motivation. In recent years it has been used as a theoretical 
framework for understanding the efficacy of motivational interventions (i.e., Markland, 
Ryan, Tobin, & Rollnick, 2005; Vansteenkiste & Sheldon, 2006). 
SDT posits that behaviour can be understood in terms of a continuum of 
autonomy (Ryan & Deci, 2000). At the far left of the continuum is amotivation, which 
occurs when an individual does not act at all, or acts without intent (e.g., "going through 
the motions"). Further up the continuum is extrinsically motivated behaviour, which is 
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thought to have four levels, with the degree of extrinsic motivation decreasing as they 
progress. The first, external regulation, describes actions done in order to satisfy an 
external demand or receive a reward. Introjected regulation describes behaviours 
designed to avoid guilt or anxiety. Individuals are thought to evidence identified 
regulation when they participate in a behaviour because they value a goal and feel it to be 
personally important. The last stage of extrinsic motivation is integrated motivation. This 
occurs when one acts in line with their values and needs. In this type of extrinsically 
motivated behaviour, actions are designed to attain desired outcomes rather than for 
inherent enjoyment. At the far right of the continuum is intrinsic regulation. Behaviours 
at this end of the continuum are intrinsically motivated and are done because they bring 
inherent enjoyment or satisfaction. The perceived locus of causality for behaviours along 
this continuum progresses from impersonal (at the amotivated end), through various 
levels of external causality (for extrinsically motivated behaviours) to internal causality 
(for intrinsically motivated behaviours). 
The SDT posits that the stability of behaviours is closely related to where they fall 
on this continuum, such that behaviour based on amotivation or perceived external 
controls will temporarily be compliant so long as these controls are in place, whereas 
intrinsically motivated changes will be stable and persistent. Available evidence supports 
this aspect of SDT. For example, lasting behavioural changes such as long-term weight 
loss (Williams, Grow, Freedman, Ryan, & Deci, 1996) and diabetes management 
(Williams, McGregor, Zeldman, Freedman, & Deci, 2004), have both been associated 
with more autonomous and intrinsically motivated reasons for participating in treatment. 
A high degree of perceived autonomy and internalized motives for behavioural change 
have also been associated with better adherence outcomes in methadone maintenance 
therapy (Zeldman, Ryan, & Fiscella, 2004). This same study showed that a high degree of 
external motivation was associated with higher rates of treatment non-compliance. 
SDT, then, would predict that CDMI will lead to better outcomes at follow-up 
relative to control, as motivational interventions are intended to promote autonomous 
motivation for change. The predicted outcome for the CDMI plus CM group was less 
clear. In the case of this combined intervention group, studies examining the effect of 
adding extrinsic rewards (i.e., externally rewarding) to intrinsically motivating (i.e., 
inherently rewarding) activities were helpful in guiding hypotheses. 
Participants in one study completed puzzles that were found to be highly 
intrinsically motivating. The experimental group received $1 for each puzzle that was 
completed while the control group received no contingent payments. Results indicated 
that solving the puzzles for money led to decreases in intrinsic motivation relative to 
controls (Deci, 1971). A second study paid college newspaper staff 50 cents for each 
headline written (an intrinsically rewarding activity). Results found, relative to controls 
who received no additional payments, a decrease in intrinsic motivation that lasted as 
long as eight weeks after the contingencies were removed (Deci, 1971). These studies 
indicate that extrinsic rewards can have deleterious effects on intrinsic motivation. This is 
because these extrinsic rewards (such as money) are thought to change the perceived 
locus of control from internal to external, resulting in decreased intrinsic motivation 
(Deci & Ryan, 1985). A meta-analysis of all available experiments such as these has 
found that tangible rewards contingent upon task performance undermine intrinsic 
motivation (Deci, Koestner, & Ryan, 1999). 
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Although smoking cessation is not intrinsically rewarding, these results were used 
to hypothesize that the combination of CDMI and monetary rewards (i.e., CM) will 
decrease intrinsic motivation for change and thereby interfere with the processes of 
CDMI. It is expected that the lack of autonomy support (considered to be a key 
component of self-determined behaviour; Deci, 1975) in the CM used in this study will 
also interfere with the process of self-motivation. It is further hypothesized, based on the 
large body of evidence for the short-term efficacy of CM, that reductions in smoking 
behaviour will be observed while the contingency phase is in place. However, the work 
of Deci (1971) suggests that this combined group will evidence higher rates of smoking 
at follow-up than individuals who received only the CDMI. 
Previous research on combined interventions 
Only two found studies examined the combination of motivational enhancement 
and contingency management. In both studies, motivation enhancement referred to a 
relatively brief intervention that used the techniques of MI to promote behaviour change. 
Budney, Higgins, Radonovich, and Novy (2000) assigned 60 individuals seeking 
outpatient treatment for marijuana dependence to one of three conditions: 1) motivational 
enhancement alone (four one-hour sessions); 2) motivational enhancement and 
behavioural coping skills therapy (14 hour-long sessions); or 3) motivational 
enhancement and behavioural coping skills therapy plus CM (14 one-hour sessions). 
Contingencies were provided for marijuana-negative urine drug screens in the amount of 
$1.50 worth of vouchers for the first negative sample, increasing by $1.50 for each 
subsequent sample in a row. Budney et al. (2000) found that the motivational 
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enhancement and behavioural coping skills plus CM group had significantly greater 
durations of marijuana abstinence than the other two groups, as well as a larger 
percentage of participants that were marijuana abstinent at the end of the study period. 
No difference was found between the motivational enhancement alone and motivational 
enhancement plus behavioural coping skills group. 
A second study built on the work of Budney et al. (2000) by adding a control 
condition and conducting follow-up assessment. In this study, 240 marijuana dependent 
participants were randomly assigned to one of four study conditions: 1) motivational 
enhancement plus cognitive behavioural therapy (nine one-hour sessions); 2) CM only; 3) 
motivational enhancement and cognitive behaviour therapy plus CM (nine one-hour 
sessions); and 4) control (Kadden, Litt, Kabela-Cormier, & Petry, 2007). In this study, 
vouchers were provided for marijuana-free urine drug screens that started at $10 for the 
first negative sample, and totalled $385 if all samples were negative. Follow-up was 
collected at post-treatment and at three-month intervals for one year. Kadden et al. (2007) 
found that the two CM groups had the best outcomes, however the CM only group had 
highest abstinence rates post-treatment, while the CM combined with motivational 
enhancement and cognitive behaviour therapy had the highest abstinence rates during the 
follow-up assessments. Despite the findings that MI has been shown to have relatively 
lasting effects on behaviour change (e.g., Project MATCH Research Group, 1997; 
Saunders et al., 1995), Kadden et al. (2007) suggest that the cognitive behavioural 
component of this combined intervention led to the higher rates of abstinence over the 
follow-up period. However, this remains speculation, as the relative contributions of the 
three interventions cannot be determined. 
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While Budney et al. (2000) and Kadden et al. (2007) were able to demonstrate the 
relative efficacy of a group that received both motivational enhancement and CM, in both 
studies these were combined with a third intervention. The addition of behavioural skills 
coping or cognitive behavioural therapy to the motivational enhancement and CM 
intervention does clearly demonstrate which of these three interventions (or combination 
of interventions) produced the larger effects. 
Therefore, this study aims to extend the earlier research by Budney et al. (2000) 
and Kadden et al. (2007) by examining the combination of only two interventions: CM 
and motivational intervention. This is expected to help further dismantle the treatment 
effects demonstrated by these two studies. The current study also aims to extend this 
approach to the treatment of nicotine dependence. 
Second research objective: Computerized intervention for nicotine dependence 
In examining this first research objective, the proposed study develops and utilizes a 
brief motivational-based computerized intervention targeting nicotine dependence 
(CDMI). It is therefore a secondary goal to evaluate the efficacy of this novel treatment-
delivery approach. 
The intervention used in this study is a motivational-based intervention similar to 
the one developed by Ondersma et al. (2005) in their study of drug-abusing post-partum 
women. Ondersma et al. (2005) found that relative to baseline, participants endorsed 
significantly higher levels of motivation to change their drug use following one session of 
CDMI. A one-month follow-up found an intervention effect of .49 (Cohen's d). The 
women also rated the intervention as highly satisfactory, easy to use, and respectful. A 
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larger scale study with 107 drug-abusing post-partum women found an odds ratio of 2.48, 
indicating that women who received the one session of CDMI were less likely to use 
illicit drugs at four-month follow-up relative to controls (Ondersma, Svikis, & Schuster, 
2007). These findings provide preliminary evidence that a computerized motivational 
intervention is effective in increasing motivation to change addictive behaviours. 
Once computer-based brief interventions such as that utilized in the current study 
are developed and evaluated, the way is paved for more widespread use. This flexible 
intervention can easily be modified (at minimal cost) so that it may be implemented in 
standard outpatient mental health clinics, substance abuse treatment programs, or 
physician's offices. It could also potentially lead to an internet-based intervention that 
may be accessed by an even larger number of people world-wide. The development and 
utilization of such programs may lead to large population effects and may have a 
significant impact on overall rates of smoking cessation. 
Summary 
This research therefore aims to examine the efficacy of a combined intervention 
of CDMI and CM relative to a control group and to CDMI alone. Primary outcomes 
include changes in smoking behaviour and in motivation to quit smoking. Motivation is a 
necessary factor in sustaining behaviour change, and CDMI is expected to primarily have 
an effect on smoking cessation by increasing this motivation to change. A secondary goal 
of this research is to develop a brief computer-delivered motivational intervention 
(CDMI) targeting smoking cessation. This approach offers many potential advantages 
over traditional MI, and previous work by Ondersma et al. (2005) and Ondersma et al., 
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(2007) has shown similar computerized interventions to be effective at reducing drug use 
amongst post-partum women. 
Following the stage model of intervention development (Rounsaville, Carroll, & 
Onken, 2001), this investigation is conceptualized as a Stage la/lb exploratory study. In 
this model, Stage I studies are designed to develop new intervention approaches, establish 
feasibility and acceptability, and estimate effect size. Stage I studies provide the basis for 
Stage II studies in which efficacy is established in an adequately powered clinical trial. 
Stage I studies are by definition not fully powered trials, but instead focus on the Stage I 
goals of acceptability, feasibility, and effect-size estimation. 
These hypotheses for this study are largely derived from SDT, which posits that 
behavioural change should be most apparent in the short term for individuals 
experiencing external motivation to change. Individuals experiencing internal motivation 
to change should evidence growing levels of motivation but not immediate reductions in 
smoking behaviour. We therefore predict differences in smoking behaviour and levels of 
motivation (during the study period and at follow-up) between the CDMI only and CDMI 
plus CM groups. The four primary hypotheses are: 1) At post-treatment and at five week 
follow-up, rates of smoking (as measured by breath carbon monoxide, saliva cotinine, 
and number of self-reported cigarettes smoked) will be lower in the two treatment groups 
(CDMI and CDMI plus CM) than in the control group; 2) At post-treatment, rates of 
smoking will be lower in the combined intervention (CDMI plus CM) than in the CDMI 
alone condition; 3) At follow-up, rates of smoking will be lower in the CDMI alone 
condition relative to CDMI plus CM; and 4) levels of self-reported motivation will be 





All participants in this study were enrolled in methadone maintenance treatment at a 
clinic in Detroit, Michigan. Consistent with other smoking cessation studies, participants 
in this study had to report smoking ten or more tobacco cigarettes on an average day 
(Frosch, Shoptaw, Nahom, & Jarvik, 2000; Schmitz, Rhoades, & Grabowski, 1995; 
Shoptaw et al., 1996; Stein & Anderson, 2003). Potential participants also had to attend 
the clinic on Mondays, Wednesdays, and Fridays, as these were the days that samples 
were taken. Potential participants were excluded from the study if they were currently 
taking the medication bupropion (Wellbutrin/Zyban), as this is an antidepressant 
medication that is also an effective smoking cessation aid. 
A total of 48 participants (16 in each group) met the above criteria and were 
enrolled in the study. Completion rates (defined as individuals still providing data at the 
end of the five week study period) were 87.5% (N=14) in the control group; 68.8% 
(N=l 1) in the CDMI only group; and 75% (N=12) in the CDMI plus CM group. Reasons 
for non-completion were that the participant left the clinic (N=4); the participant failed to 
meet regularly with the researcher (N=4); or that the participant asked to withdraw from 
the study (N=3). No significant pattern to non-completion was found across the three 
groups. Data analysis was conducted only on completers. 
Participants tended to be middle-aged (M= 50 years, range = 26 to 66), female 
(65%), and African American (81%). The modal level of education was General 
Educational Development (GED; High School equivalent) level, with 14% having 
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completed less than Grade 10 and 22% having some college or university. With respect 
to socioeconomic status, 84% of the sample was unemployed and 49% had an income of 
less than $500 per month. 
The average participant had a long history of cigarette use (M= 30 years; range = 5 
to 50 years). Participants had tried to quit an average of six times in their life, and 
currently smoked a mean of 15 cigarettes per day. Rates of illicit drug use were also high 
in this sample, as urine drug screens in the five weeks prior to the study were frequently 
positive for cocaine and opiates (43% and 34% of the samples, respectively). 
Procedure 
All procedures used in this study were approved by the University of Windsor's 
Research Ethics Board (Appendix A) and Wayne State University's Human Investigation 
Committee (Appendix B). Potential participants were approached in the clinic waiting 
area and asked to complete a brief questionnaire related to their use of tobacco (Appendix 
C). The investigator explained that by completing this questionnaire, they might be 
contacted about a research study where they had the opportunity to earn $70 or more in 
gift cards. Screened individuals earned a $1 gift certificate (see Appendix D for study 
expenses). McDonald's and Target gift certificates were used throughout this study. 
To maintain confidentiality while ensuring the ability to match responses to 
particular participants, all questionnaires were assigned a unique participant code. 
Baseline 
Participants provided consent to participate in the study (Appendix E) and were 
then provided with a list of stop smoking resources (both phone and internet-based; 
Appendix F). This assured that all participants, including those in the control condition, 
had support available to them for any quit attempt they chose to make. Participants were 
then randomly assigned to one of the three study groups using a modified matched-pairs 
approach to ensure group equivalence on gender and ethnicity. Matching the groups on 
major demographic criteria allows for a maximal ability to speculate on any differential 
effects of the interventions. In particular, groups were matched on ethnicity because of 
previous findings that the effects of MI are larger for minority samples (Hettema et al., 
2005). 
Following the receipt of informed consent and random assignment to the study 
condition, the investigator introduced the participant to the computer, which was used to 
gather all background information and to administer all baseline questionnaires other than 
the Timeline Followback (a measure used to assess number of cigarettes smoked in the 
past thirty days), which was completed by hand (see Table 1 for timeline of measures 
administered throughout the study). Participants were given the choice between using a 
mouse or touch-screen system. Participants received a $5 gift certificate for completing 
these initial questionnaires (see Appendix G for the timeline of payments throughout the 
study). 
Across all three groups, the first week of the study was the baseline period. The 
purpose of this baseline was to record the participants' level of smoking prior to the 
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Table 1 (continued) 
Timeline of measures. 
Baseline 
Secondary Measures 
Fagerstrom Test for Nicotine X 
Dependence 
Smoking Self-Efficacy X 
Questionnaire 
Readiness to Change X 
Questionnaire 
Stages of Change Algorithm X 
Negative Effects of Smoking 
Control Group 
Intervention Groups X 
Attributes of Treatment 
Measure 
Motivation for Change 
Questionnaire 
Table 1 (continued) 
Timeline of measures. 
Treatment Self-Regulation 
Questionnaire 
Illicit drug use 
Baseline Week 1 
X 
Week 2 Week 3 Week 4 Post-study Follow-up 
X 
X 
intervention, as this afforded the ability to test for within-subject effects. During this 
baseline, participants were asked to provide a breath CO reading and complete (by hand) 
the Tobacco Use and Beliefs Measure (used to assess motivation to quit and confidence 
in ability to quit) and the Brief Tobacco Quantity Assessment (used to assess number of 
cigarettes smoked in the past several days) on three occasions (Monday, Wednesday, and 
Friday). Saliva cotinine was also randomly collected on one of these days. During the 
baseline period, all participants were compensated with $2 in gift certificates each time 
they provided a breath CO sample and completed the brief measures. 
Intervention 
Following the one-week baseline period, the CDMI only and CDMI plus CM 
groups underwent the first of two computerized CDMI sessions (Appendix H). 
Individuals in the control condition interacted with the computer on a non-smoking 
related task (Appendix I). The fact that all participants interacted with the computer 
helped control for any computer-related effects. 
The intervention lasted approximately 20 minutes and was individually tailored to 
each participant. It consisted of three main components: 
1) Pros and cons of tobacco use, in which the participant chose from a list of options the 
positive and negative aspects of tobacco use for them (e.g., "Smoking helps me relax and 
deal with stress", "Smoking helps me lose weight or maintain my current weight", 
"Smoking increases my risk of cancer and other diseases", "Smoking makes my face and 
body look older", see Figure 1). 
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Things I like about smoking 
What are some of the things you like about your smoking? 
* 
• Smoking feels good • I like watching the smoke and 
the cigarette burn 
a Smoking helps me relax and deal with • Smoking keeps away 
stress withdrawals 
• Smoking can be a good way to socialize • I like taking smoke breaks 
and bond with other smokers throughout the day 
a Smoking makes things more enjoyable • Something else that is not on 
this list 
n Smoking helps me lose weight or a None of these options 
maintain my current weight 
^ r e p e a t ^previous: • : - ^ i i ex t J | p a use < " ^ M o p 
Figure 1. Example of pros and cons of tobacco use. 
2) Feedback regarding the specific negative financial and health-related aspects unique to 
their level of smoking (i.e., the amount of money per year they spend on cigarettes, the 
percentage of adults who are non-smokers and how this percentage has increased over 
time, how their negative effects from smoking compare to other smokers, and how much 
higher their breath CO is than that of a non-smoker, see Figure 2). 
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Figure 2. Example of personalized feedback regarding level of smoking. 
3) Optional goal-setting regarding smoking, followed by a questions from the Change 
Plan Worksheet (Miller & Rollnick, 1991, see Figure 3) to help the participant clarify 
their goals and plan for obstacles (e.g., their specific reasons for quitting; the steps they 
plan to take in quitting; and what could interfere with their change plan goal). 
Using pre-planned algorithms, participants who were initially willing to set a quit 
date proceeded directly to the third component. Those initially unwilling to set a quit date 
engaged in the first and second component. For those participants who reached the end of 
the second component and were still unwilling to set a quit date, the computer reflected 
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Plan for Change r . WA^STATE :" 
How will I know if my plan is working? ^ H ^ K IT 
How will you know If your plan to quit smoking Is working? 
• If I can go a full day or week without • If other people notice the changes 
smoking I am making 
• If I have fewer cravings for cigarettes • If I can walk into a corner store 
and not buy cigarettes 
o If I can cut the number of cigarettes I • If I can refuse a cigarette that is 
smoke in at least half offered to me 
a If I begin to feel like a non-smoker • Something else not on this list 
0 If my breathing and lung functioning D None of these options 
improves 
BM repeat ^previous ; pnex l gjpaus© l3j|gtop 
Figure 3. Example of optional goal setting regarding tobacco use. 
their lack of readiness to change at this time and elicited information regarding 
what signs would tell the participant that he/she did need to change. 
Throughout this intervention, an animated and emotionally expressive cartoon 
character acted as a narrator and guided the participant through the process. The narrator 
read each item and also reflected back the participant's answers. This narrator, as well as 
the touch-screen computer system, ensured that participants with minimal computer 
literacy or poor reading skills could easily use and understand this computer program. 
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A second CDMI session was administered at the end of the study period, 
approximately four weeks after the initial intervention. This was done as an attempt to 
boost motivation prior to follow-up and engage participants who may have not been 
initially willing to set a quit date. It was also felt that a second intervention was needed 
because within the context of brief interventions, more intervention time has been found 
to be beneficial (Burke et al., 2003). As most relapses occur within a few weeks of 
quitting, it was felt that a second CDMI within a relatively short time period may help to 
increase or sustain the motivation of any participants who may have returned to baseline 
levels of smoking. 
The timing of this second intervention was chosen to be at the end of the study 
period in part because of the nature of the pre-planned algorithms. It was felt that 
engaging in the same (or very similar) intervention at a short time interval may not be of 
much benefit or interest to participants. This second intervention also began by assessing 
the participant's motivation for quitting and followed the same pre-planned algorithms as 
the first session. The control group also underwent a second session with the computer on 
a non-smoking-related task. At the completion of each of the two sessions, participants 
were compensated with a $10 gift certificate. 
Study period 
Consistent with other investigations, the study period lasted a total of four weeks 
(Robles et al., 2005; Shoptaw et al., 1996). During this time, all participants continued to 
provide thrice weekly breath CO samples and complete the Tobacco Use and Beliefs 
Measure and Brief Tobacco Quantity Assessment each time they provided a sample 
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(Mondays, Wednesdays, and Fridays). Saliva cotinine was also randomly tested once a 
week during this time. The only difference was in how the groups were compensated: 
CDMI only and control group: These participants received $2 in gift certificates each 
time they provided a breath CO sample and completed the brief questionnaires. This 
compensation was provided regardless of the level of their breath CO. The fact that this 
payment was non-contingent upon their smoking was stressed to these participants 
through the study. Participants in these groups earned up to $30 in gift cards for 
providing these samples, and $75 in gift cards overall. 
CDMI plus CM group: This group primarily received compensation based on whether or 
not they provided breath CO samples indicating a recent abstinence from cigarettes. In 
order to receive this payment, their saliva cotinine also had to test below the cut-off on 
the random days they were asked to provide this sample. 
Participants in this condition earned $4 in gift cards for the first sample they 
provided that indicated recent smoking abstinence. Consistent with Robles et al. (2005), 
this amount increased by 50 cents for each consecutive day that they remained abstinent. 
Participants could therefore earn $4.50 on Day 2, $5 on Day 3, and so on, up to a 
maximum of $9.50 on Day 12. A sample that tested above the cut-off did not earn the 
participant any compensation, and the amount they could earn the following day was 
reset to $4. Budney et al. (2000) also used this incremental earning system in their study 
of the combined effects of motivational enhancement and CM on marijuana use. 
These participants also earned $1 in gift certificates for each time that they 
provided a breath CO sample and completed the brief questionnaires. This payment was 
provided even if the sample tested positive for recent tobacco use. This nominal payment 
helped ensure that individuals who did not reduce their smoking still had some incentive 
to continue to provide breath CO samples and information on the number of cigarettes 
they had smoked. 
The amount earned by participants in this group was therefore dependent on how 
many negative samples they provided. For completing all parts of this study, participants 
in this group earned $60. A participant that provided negative samples on each of the 12 
days of the study would earn an additional $81. This potential payment amount falls 
within the range of CM reinforcers reported in the literature. For example, reductions in 
cocaine abuse amongst methadone maintenance clients have been reported with CM 
payments as high as $3,369 (Dallery, Silverman, Chutuape, Bigelow, & Stitzer, 2001) 
and as low as $25 per individual (Rowan-Szal, Bartholomew, Chatman, & Simpson, 
2005). 
Post-study 
At the end of the five-week study period, all participants completed the following 
questionnaires and were compensated with $5 in gift cards: 
• Fagerstrom Test for Nicotine Dependence 
• Smoking Self-Efficacy Questionnaire-12 
• Readiness to Change Questionnaire 
• Stages of Change Algorithm 
• Negative Effects of Smoking Questionnaire 
• Attributes of Treatment Questionnaire 
• Motivation for Change Questionnaire 
• Treatment Self-Regulation Questionnaire 
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Follow-up 
Follow-ups were conducted with all participants five weeks after study completion. 
These follow-ups consisted of a breath CO sample, a saliva cotinine sample, and the 
following questionnaires: 
• Fagerstrom Test for Nicotine Dependence 
• Smoking Self-Efficacy Questionnaire-12 
• Readiness to Change Questionnaire 
Stages of Change Algorithm 
• Timeline Followback 
• Tobacco Use and Beliefs Measure. 
Participants were compensated with $15 in gift cards for completing this follow-up. 
Follow-up rates were 100% for the control group (N = 14); 100% for the MI only group 
(N = 11); and 91.7% for the MI plus CM group (N = 11). At the end of the follow-up, 
participants in the control group were offered the motivational intervention. 
Measures 
Primary Measures 
Demographics Questionnaire. This questionnaire records information regarding age, 
gender, highest level of education obtained, and questions related to socioeconomic status 
(Appendix J). This questionnaire was computer-administered at baseline. 
Smoking Background Questionnaire. This brief questionnaire assesses such variables as 
age of first use of tobacco, number of years of use, and number of previous quit attempts 
(Appendix K). This questionnaire was computer administered at baseline. 
Breath carbon monoxide (CO). Breath CO readings were taken with the piCO-LO 
Smokerlyzer Monitor® from Bedfont Scientific Ltd. Readings below 10 ppm place 
individuals in the non-smoking range. According to the Bedfont website 
(www.bedfont.com/downloads/Micro+.pdf), this product has a sensitivity of 1 ppm and 
an accuracy of ± 2%. The breath CO readings were taken three times during the baseline 
week, three times a week throughout the study period (12 samples total), and during the 
follow-up assessment. 
Saliva cotinine. Cotinine is the principal metabolite of nicotine. The NicAlert© Saliva 
Nicotine Test was used to assess cotinine levels. This is a semi-quantitative and highly 
sensitive test that detects levels ranging from 0 ng/ml to 1000+ ng/ml. Test readings 
range from 0 (0-10 ng/ml) to 6 (1000+ ng/ml). A positive test is considered anything 
above 10 ng/ml. Research has shown this test to have a specificity of 95% and a 
sensitivity of 93% (Cooke, Bullen, Whittaker, McRobbie, Chen, & Walker, 2008). This 
test requires participants to place a sample of oral fluid into a small collection container. 
This fluid is then placed on a test strip, and results are visibly obtained within minutes. 
This test was administered once during the baseline period, once a week throughout the 
four-week study period (the day was chosen at random for each participant), and once at 
follow-up. Participants were told that saliva samples were collected once per week but 
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the day was not know to them ahead of time. Saliva cotinine was collected in addition to 
breath CO, as the 17-hour half-life and a 48 hour window of detection of cotinine (Robles 
et al., 2005) is much greater than that of breath CO. The cotinine test was only 
administered once a week throughout the study, as the cost of these tests was prohibitive. 
Timeline Followback (Sobell & Sobell, 1996). This measure was used to assess the 
participant's tobacco use within the past 30 days (Appendix L). It was administered by 
paper and pencil at baseline and follow-up. It was not necessary to administer this 
measure at the end of the study period, as the Brief Tobacco Quantity Assessment (see 
below) captured tobacco use during the 28-day study period. The Timeline Followback 
makes use of a calendar with important dates and holidays noted. The participant is also 
encouraged to record any personal markers, such as birthdays or significant life events. 
Using these dates to enhance their recall, participants provide retrospective estimates for 
their tobacco use over the specified time period. 
The Timeline Followback method has been validated as a measure of tobacco use 
(e.g., Shiffman, Paty, Kassel, Gnys, & Zettler-Segal, 1994) and is recommended for use 
in evaluating specific changes in drug or alcohol use before and after treatment (Sobell & 
Sobell, 1996). Several studies have shown the Timeline Followback to be quite reliable 
over time, with the majority of test-retest correlations greater than .85 (Sobell & Sobell, 
1996). It is considered the gold standard for self-report of tobacco use. 
Brief Tobacco Quantity Assessment. This brief measure was administered by paper and 
pencil three times a week throughout the baseline and study period. It asked the 
participant to indicate how many cigarettes they have smoked since the last assessment 
point (Appendix M). This allowed for a daily assessment of tobacco use throughout the 
entire study period. 
Tobacco Use and Beliefs Measure. This is a brief measure that has been modified from 
the contemplation ladder (Biener & Abrams, 1991), a validated measure of smoking 
cessation change. Using visual analogue scales (VAS), participants were asked to rate: 1) 
their motivation to quit smoking, and 2) their confidence that they will be able to quit 
(Appendix N). The VAS is a 10-centimeter line, on which the participant marks a point 
between two anchors (i.e., 'not at all' and 'extremely'). The response is scored based on 
how many millimeters from the left anchor the participant's mark is placed. This measure 
was completed by paper and pencil three times a week throughout the baseline and study 
period, and during the follow-up assessment. 
Secondary Measures 
Fagerstrom Test for Nicotine Dependence (Heatherton, Kozlowski, Frecker, & 
Fagerstrom, 1991). This is a 6-item questionnaire that assesses one's level of dependence 
on nicotine (Appendix O). Items include 'How soon after you wake up do you smoke 
your first cigarette?' and 'Do you find it difficult to refrain from smoking in places where 
it is forbidden?'. Scores can range from 0 (no to low dependence) to 10 (very high 
dependence). This measure has been shown to have acceptable internal consistency 
(Cronbach's alpha of .68; Etter, 2005) and has been found to be significantly correlated 
with saliva cotinine levels (Pomerleau, Carton, Lutzke, Flessland, & Pomerleau, 1994). 
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This questionnaire was completed on the computer at baseline, study completion, and 
during the follow-up assessment. 
Smoking Self-Efficacy Questionnaire-12 (Etter, Bergman, Humair, & Perneger, 2000). 
This 12-item scale assesses the confidence of smokers in their ability to abstain from 
smoking in high-risk situations (Appendix P). This questionnaire includes both an 
internal stimuli subscale (e.g., "When I feel depressed") and an external stimuli subscale 
(e.g., "When I am with smokers"). Responses are given on a 5-point Likert scale ranging 
from "Not at all sure" to "Absolutely sure". This measure has been shown to have 
acceptable validity, high test-retest reliability (correlation coefficient of .95 for the 
internal subscale and .94 for the external subscale; Etter et al., 2000), and high internal 
consistency (Cronbach's alpha of .95 for the internal subscale and .94 for the external 
subscale; Etter et al., 2000). This questionnaire was completed on the computer at 
baseline, study completion, and during the follow-up assessment. 
Readiness to Change Questionnaire (Rollnick, Heather, Gold, & Hall, 1992). This is a 
12-item questionnaire designed to assess an individual's stage of change (Appendix Q). 
The original questionnaire was designed to measure readiness to change problem 
drinking, however for the purposes of this study the items have been modified to assess 
tobacco use. There are three subscales: Precontemplation (e.g., "I don't think I smoke too 
much); Contemplation (e.g., "Sometimes I think I should cut down on my smoking"); and 
Action (e.g., "I have just recently cut down on my smoking"). Responses to each item are 
given on a 5-point Likert scale ranging from -2 (strongly disagree) to +2 (strongly agree). 
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An individual is said to be in the stage of change with the highest subscale score. This 
measure has been found to have acceptable internal consistency (Cronbach's alpha of .73 
for the precontemplation subscale, .80 for the contemplation subscale, and .85 for the 
action subscale; Rollnick et al., 1992) and high test-retest reliability (correlation 
coefficient of .82 for the precontemplation subscale, .86 for the contemplation subscale, 
and .78 for the action subscale; Rollnick et al., 1992). This questionnaire was completed 
on the computer at baseline, study completion, and during the follow-up assessment. 
Stages of Change Algorithm (DiClemente et al., 1991). This single item measure ("Are 
you seriously thinking of quitting smoking?") places individuals in different stages of 
change based on their response (see Appendix R). There are four stages of change: 
Precontemplation, Contemplation, Preparation, Action / Maintenance. This questionnaire 
was administered at baseline, study completion, and at follow-up. 
Negative Effects of Smoking Questionnaire. This is a 20-item questionnaire with items 
from the Short Inventory of Problems (Miller, Tonigan, & Longabaugh, 1995) modified 
to focus on cigarette smoking, as well as author-compiled items (Appendix S). This 
questionnaire was administered to participants in the two motivational intervention 
groups (CDMI only and CDMI plus CM) as part of the questionnaire package that they 
completed at baseline, the end of the study period, and at follow-up. Control participants 
only received this questionnaire at the end of the study period and at follow-up. It was 
desired to use this as an outcome measure for all participants, although it was felt that 
asking participants about the negative effects of their smoking may serve to increase their 
motivation for change. To avoid having such a motivational effect on the control group, 
these individuals did not complete the questionnaire at the beginning of the study period. 
Attributes of Treatment Questionnaire. This author-compiled 12-item measure assesses 
how participants feel about the treatment they received in this study (Appendix T). 
Participants were reminded that this treatment includes any gift cards they received, the 
time they spent with the computer, and any interactions they had with the researcher. 
Items include "The treatment I received was respectful"; "The treatment I received was 
unsupportive"; "The treatment I received made it worthwhile to change for a little bit" 
and are answered on a 1 (Strongly disagree) to 5 (Strongly agree) Likert Scale. This 
measure was computer-administered at study completion. 
Motivation for Change Questionnaire. This author-compiled measure consists of five 
items assessing internal motivation for change (e.g., "It was a goal I had set for myself) 
and five items assessing external motivation for change (e.g., "I got paid for doing it") 
(Appendix U). Responses are given on a 1 (Strongly disagree) to 5 (Strongly agree) 
Likert Scale. This questionnaire was computer-administered at study completion. 
Treatment Self-Regulation Questionnaire (Williams, Freedman, & Deci, 1998). This 
15-item measure assesses motivation for change and includes items assessing 
autonomous (e.g., "Because I felt I wanted to take responsibility for my own health"), 
controlled (e.g., "Because it was easier to do what I am told than to think about it), and 
amotivated (e.g., "I really didn't think about it") motivation (Appendix V). Responses are 
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given on a 1 (Not at all true) to 5 (Very true) Likert Scale. This questionnaire was 
administered at study completion. 
Illicit drug use. Clinic clients provide frequent urine drug screens as part of their 
methadone treatment. These drug screens indicate recent use of opiates and cocaine. 
Participants in this study used other illicit substances too infrequently to be able to 
statistically analyse any changes over time. The information from these drug screens was 
valuable to the present study because some studies have found that when individuals quit 
smoking, there tends to be reductions in overall substance use (e.g., Prochaska, Delucchi, 
& Hall, 2004). This has also been found in a methadone-maintained sample of 
individuals. Specifically, participants in a smoking cessation program provided more 
opiate- and cocaine-free urines in the weeks that they meet criteria for smoking 
abstinence (Shoptaw et al., 2002). It is thought that this occurs at least in part because 
cigarette smoking is often a cue for alcohol or drug use. 
Chapter 111 
RESULTS 
Data cleaning and evaluation 
Missing data 
As this was a longitudinal study and involved several time points, addressing 
missing data was particularly important before data analysis could begin. The average 
percent of days that participants failed to provide data (i.e., breath CO, self-reported 
number of cigarettes smoked, and VAS ratings) throughout the study was 16% for 
participants in the control group; 12% in the CDMI only group; and 19% in the CDMI 
plus CM group. A one-way ANOVA found no significant difference between the groups 
on this variable, F(2,34) = 1.16,/? = .33. 
Intention to treat analysis is one method to analyze randomized controlled trials. 
This method compares participants in the groups to which they were randomly assigned 
regardless of their subsequent withdrawal or the treatment that they actually received 
(Hollis & Campbell, 1999). This ensures that clinical effectiveness is not overestimated. 
Although the application of this method varies widely in the literature, intention to treat 
analysis is only possible when outcome data is available for all randomized participants 
(Hollis & Campbell, 1999). Outcome data was not available for all participants who 
enrolled in this study, and therefore sensitivity analysis was a more appropriate 
procedure. 
To address the issue of missing data, forward replacement was used for 
participants who failed to provide data on no more than one day in a row and who missed 
< 20% of the overall study days. Missing data for participants who missed more than two 
days in a row or who had missing data for > 20% of the study days were averaged 
between their day prior to and after the missing days. In order to assess the potential 
impact of this missing data, we ran a sensitivity analysis on the main outcome measures 
(breath CO, saliva, number of cigarettes smoked, and self-reported motivation to quit). 
Participants for whom complete data was available were compared to participants for 
whom data replacement techniques were used. No significant differences were found. 
Differential follow-up rates were not analyzed, as only one participant of those 
that completed the study was not available for follow-up assessment. As mentioned 
previously, rates of study completion were not found to significantly differ between the 
three groups. 
Skewness 
All variables were evaluated for skewness, and any showing over two standard 
errors of skewness (Tabachnick & Fidell, 1996) were transformed. For this study (JV = 
37), the critical value was .80. The analyses below are all based on variables that meet the 
assumptions for ANOVA, although the details of each transformation are not reported. 
For the main findings reported below, six of the variables required transformation, 
with the most frequent being a square root transform. 
Approach to data analysis 
Current models of intervention development recommend a staged approach, part 
of which includes an emphasis on appropriate pilot testing (exploring feasibility, 
acceptability, and effect size estimation) prior to beginning fully powered Stage/Phase III 
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clinical trials (Rounsaville et al., 2001). As noted above, this study was designed and 
executed from within this conceptual framework. For this reason, in addition to the small 
effects typically seen in smoking cessation studies (requiring very large sample sizes in 
order to obtain significant effects; Lancaster & Stead, 2006a), null-hypothesis 
significance testing was not the most appropriate means of evaluating these data. Rather 
than relying solely on the criteria of statistical significance to guide our understanding of 
the intervention effects, greater weight was given to patterns in the data and to measures 
of effect size. This allowed for a more exploratory analysis of the findings and allowed us 
to examine non-linear effects beyond the capacity of ANOVAs. 
To conduct these exploratory analyses, ap value cut-off of < .30 was used. Any 
group main effects or time x group interactions that had ap value under this level were 
explored further with post-hoc tests and estimates of effect size. 
Estimates of effect size were calculated using Cohen's d, d- (meam - mean2) / 
(SDi" + SD2" / 2)"-', in cases where outcomes were continuous. According to Cohen 
(1992), 0.2 is indicative of a small effect, 0.5 a medium effect, and 0.8 a large effect size. 
In most cases, d was calculated using change scores (either post-study minus baseline or 
follow-up minus baseline) in order to control for baseline values. 
Change scores could not be calculated for repeated measures analyses. For these 
analyses, partial eta-squared (n p), a measure of effect size that is based on proportion of 
variance accounted for rather than standard deviations, was obtained. This value was then 
utilized to calculate Cohen's d, using the formula d - (2r 11- r2)05. (Note: since partial 
eta-squared is most accurate as a measure of effect size when the number of groups is two 
[k = 2], separate repeated measures analyses comparing two groups at a time were run). 
The main findings are presented here, although further results may be found in 
Appendixes W-AC. 
Tests of group equivalence 
Demographics 
The three groups were found to be equivalent on all key demographic variables. 
As shown in Table 2, analyses of categorical variables through chi-square tests found no 
difference between the groups on gender, x2 (2) = .50, p = .78; ethnicity, x2 (4) = .30,p -
.99; level of education, x2 (10) = 9.42,/? = .49; employment status, x2 (4) = 3.02,;? = .55; 
or monthly income, X2 (8) = 6.03,/? = .64. It was also found that neither age, F(2,34) = 
1.68,/? = .20, or number of days in treatment, F(2,33) = .44, p = .65, were significantly 
different between the groups. 
Baseline smoking measures 
The three groups were equivalent on all key baseline smoking variables. No 
significant difference between the groups was found on: age of first cigarette, F(2,33) = 
1.22,/? = .31; age of first regular use of cigarettes, F(2,34) = .86,/? = .43; number of quit 
attempts, F(2,32) = .58,/? = .57; number of total years smoked, F(2,34) = 2.60, p = .09; 
longest time without a cigarette, F(2,33) = 2.06, p = .14; money spent each week on 
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Baseline smoking statistcsfor each study group. 
Control 
Variable 
CDMI only CDMI plus CM 
Mean (SD) Mean (SD) Mean (SD) 
Age of first cigarette 
Age when started smoking regularly 
Number of total years smoked 
Number of times tried to quit 
Longest time without a cigarette (days) 136.0 (221.1) 
Number of cigarettes each day 
Amount spent each week on cigarettes ($) 31.5 (20.4) 
Have you ever talked to your counsellor 































The average additional amount earned by participants in the CDMI plus CM 
group was $16.35 (SD - $20.77, range = $0 to $56.50). The maximum that could be 
earned was $81. 
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Breath CO 
The overall pattern of breath CO indicates a small increase in breath CO for the 
control and CDMI only groups (each up approximately 10%) during the 5-week study 
period, and a small to moderate decrease in breath CO for the CDMI plus CM group (a 
decrease of approximately 25%; Figure 4). 
Breath CO summary 
The analyses are consistent in demonstrating the efficacy of the combination of 
CDMI and CM in producing a during-treatment reduction in breath CO relative to control 
and CDMI alone. To a lesser degree, there was also an effect for CDMI alone, relative to 
control. This pattern of results reached the level of statistical significance for analyses of 
breath CO reductions of 50% relative to baseline. The increased efficacy of the CDMI 
plus CM group was only evident during treatment, and did not extend to the follow-up 
period. 
During treatment repeated measures 
Statistical analysis of these values over the study period was done using a 
repeated measures ANCOVA on breath CO readings for Week 1, Week 2, Week 3, and 
Week 4(12 readings total). The covariate was average breath CO reading for the baseline 
week. There was a non-significant trend towards a group main effect, F(2,32) = 2.46, p = 
.10, r|2p = .13. No significant main effects were found for time, F(9,352) = 1.14,/? = .34, 
















Baseline Week 1 Week 2 Week 3 Week 4 Follow-up 
Figure 4. Average breath CO values across the study period and follow-up (fixed to zero 
to account for baseline differences). 
Given that the;? value for the group effect was well below the cut-off value of .30, 
further exploration of these data was conducted. Partial eta squared values were 
calculated for two group comparisons and were converted to Cohen's d. Across the study 
period, the CDMI plus CM group showed a larger magnitude of reduction in breath CO 
relative to CDMI alone (d= .82) and control (d= .97). There was a moderate effect size 
difference between CDMI only and control (d= .52). This suggests that there was a clear 
advantage for the combination of CDMI and CM in reducing breath CO over the length 
of the study period. 
Baseline versus post-treatment 
Change scores were then calculated from baseline to Week 4. The difference in 
these change scores between the groups approached significance, F(2,34) = 2.70, p = .08, 
r|2p = .14. Because this;? value was well below the cut-off of .30, more statistical 
exploration of this data was conducted. 
Further analyses (Fisher's LSD post-hocs) revealed a significant difference 
between the control and CDMI plus CM group (Mean Difference = 8.14,/? = .04) and a 
non-significant trend towards a difference between the CDMI only and CDMI plus CM 
group (Mean Difference = 6.89, p = .09). The CDMI plus CM group decreased their 
breath CO while the other two groups increased from baseline to Week 4. No significant 
difference was found between CDMI only and control (Mean Difference = 1.25, p = .74). 
Change scores revealed a large effect size magnitude for the CDMI and CM 
group over the CDMI only (d= .81) and the control group (d=l.\T). The magnitude of 
the difference on breath CO between the CDMI only and control group was almost zero 
(d= .12). This also suggests that there was a clear advantage for the combination of 
CDMI and CM on reducing breath CO levels at the end of the study relative to baseline. 
Baseline versus follow-up 
A statistical analysis of the breath CO follow-up data (controlling for baseline CO 
levels) found no significant group differences, F(2,30) = .56,p = .58, n2p =.04. Because 
this p value was above the cut-off of p<30, more statistical analyses were not conducted. 
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Number of days breath CO was in non-smoking range 
The total number of days breath CO was in the non-smoking range was compared 
across the three groups (Figure 5). Statistical analysis using an ANCOVA (covarying on 
baseline breath CO) showed a non-significant trend at thep < .30 level, F(2,32) = 1.71,/? 
= .20, r|2p =.10. Two group comparisons were run and partial eta-squared was used to 
calculate Cohen's d. In terms of magnitude of change, the CDMI plus CM group showed 
more samples in the non-smoker range than the other two groups (d = .70 versus CDMI 
only and d = .95 versus control), and the CDMI only group had more non-smoker 
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Figure 5. Total number of days across the study period that breath CO was in the non-
smoker range (error bars are standard deviation values). 
Breath CO reductions relative to baseline 
The number of days across the four weeks of the study that each participant had 
reduced their breath CO reading by 50% relative to their average reading during the 
baseline week was calculated (Figure 6). A univariate ANOVA was run on these data, 
and a significant group difference was found, F(2,34) = 5.07,p = .01, if p =23. Further 
analyses (Fisher's LSD post-hocs) indicated that the control group had significantly 
fewer days of breath CO reduced by 50% relative to baseline than the CDMI only (Mean 
Difference = .l2,p = .03) and the CDMI plus CM (Mean Difference = .16,/? < .01) 
groups. There was no significant difference between the CDMI only and CDMI plus CM 
groups (Mean Difference = .04, p = .47). 
Estimates of effect size revealed that there was a large effect when the control 
group was compared to the CDMI only (d = 1.10) and CDMI plus CM groups (d=l.l7), 
with the control group producing fewer samples that met this 50% reduction criterion. 
When the CDMI only group was compared to the CDMI plus CM group, a moderate 
effect was found (c/= .54), with the combined intervention group producing the largest 
number of samples that showed a 50% reduction. 
Measure of clinically significant breath CO reductions 
A clinically significant reduction in breath CO was defined as a 25% decrease 
relative to baseline. An ANOVA on follow-up breath CO values indicated no difference 
between the groups on this value, F(2,30) = 1.38,/? - .27, although nine of the 35 
participants provided follow-up samples below this cut-off. 
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Figure 6. Number of days across the study period that breath CO was reduced 50% 
relative to baseline (error bars are standard deviation values). 
Saliva cotinine 
The saliva cotinine readings across all participants decreased slightly between 
baseline and Week 1 but then slowly increased, such that Week 4 readings were slightly 
higher than baseline levels. When each of the three groups was examined separately, no 
clear pattern of results emerged (Figure 7). The average saliva cotinine reading was in the 
moderate range (modal score of 4 with a possible range = 0-6). At follow-up, all three 













Baseline Week 1 Week 2 Week 3 Week 4 Follow-up 
Figure 7, Saliva cotinine values across the study period and follow-up (fixed to zero to 
account for baseline differences) 
Summary of saliva cotinine findings 
There were no significant differences in saliva cotinine levels, either during 
treatment or at follow-up. 
Saliva cotinine across the study period 
Statistical analysis of Week 1 to Week 4 values (using a repeated measures 
ANCOVA with baseline saliva cotinine as the covariate) revealed no significant main 
effects of time, F(3,99) = .82, p = .49, n2p =.02, or group, F(2,33) = .48,/? = .62, n
2
p =.03, 
and no time by group interaction, F(6,99) = .49, p = .81, r| p =.03. Analysis of change 
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scores also suggested no treatment effects on saliva cotinine readings at Week 4, F(2,34) 
= .18, /? = .84,n2p = 01. 
Saliva cotinine at follow-up 
Similarly, no significant group differences were found on the change scores at 
follow-up (controlling for baseline values), F(2,31) = .18,/? = .84, r\ p =.01. 
Number of self-reported cigarettes 
Across the study period 
The pattern of results for all participants shows that from baseline to Week 1, 
participants reduced their smoking from approximately 14 cigarettes per day to 10 
cigarettes per day. Looking at the pattern of results for each of the three groups suggests 
that the control and CDMI plus CM groups showed some degree of reduction each week 
of the study. The CDMI only group showed reductions from baseline to Week 2, and then 
increased the number of cigarettes smoked during Weeks 3 and 4 (although not back to 
baseline levels). 
The control and CDMI participants reduced their cigarette use by on average 20 
cigarettes a week over the five weeks of the study, while CDMI plus CM participants 
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Figure 8. Number of self-reported cigarettes each week of the study period (total value) 
Summary of findings for self-reported number of cigarettes 
These results suggest that all three groups reduced their levels of self-reported 
smoking over the study period to a similar degree, and that no clear advantage of one 
intervention over the others was apparent. At follow-up, all three groups also maintained 
this reduction relative to baseline levels. However, non-significant trends suggested that 
the CDMI only group made additional post-treatment changes, whereas the CDMI plus 
CM group increased use after the removal of treatment. This diverging trend led to an 
apparent advantage for CDMI only in terms of change from post-treatment to follow-up. 
During treatment repeated measures 
Statistical analysis of the linear pattern of results was done using repeated 
measures ANCOVA. The within subjects variables were the total number of cigarettes 
smoked during each of the four weeks of the study and the covariate was total number of 
cigarettes smoked during the baseline week. This analysis revealed no main effect of 
time, F(7,864) = 1.65,;? = .13, r|2p = .05, or group, F(13,864) = .71,p = .75, n
2
p = .04, 
and no time by group interaction, F(2,32) = 35, p = .71, n2p = .02. 
Baseline versus post-treatment 
Change scores were calculated for the number of cigarettes smoked during Week 
4 minus the number of cigarettes smoked during the baseline week. These differences 
were not significant across the three groups, F(2,34) = .31,/? = .74, n p = .02. Because the 
p value was greater than .30, no further analyses were conducted. 
Across pre-study, study period, and post-study 
Participants overall showed a reduction in number of cigarettes smoked from 
baseline to post-treatment (from 14 to 10 cigarettes/day, or approximately 6.5 fewer 
packs of cigarettes a month). This reduction remained almost constant at follow-up 
(Figure 9). Looking at the three groups separately revealed that the control group 
followed this same pattern (i.e., sharply reduced the number of cigarettes they smoked 
relative to pre-study and maintained this level at follow-up). The CDMI only group also 
drastically reduced their use of cigarettes relative to pre-study and then continued this 
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Figure 9. Total number of cigarettes smoked pre-study (30 days), during the study period 
(28 days), and post-study (30 days). 
CM group reduced their use of cigarettes to a similar degree during the study period, but 
then increased their use of cigarettes by approximately one per day at follow-up (still 
down three cigarettes a day, or almost five packs per month, relative to pre-study). 
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Pre-study versus study period 
Analysis of the number of cigarettes smoked during the study period, minus pre-
study levels of smoking showed similar levels of reduction across all three groups, 
F(2,34) = .14,/? = .87,n2p = 01. 
Pre-study versus post-study 
Change scores were also calculated for the number of cigarettes smoked post-
study, minus pre-study. No difference between the groups was found, F(2,33) = .23, p -
.80,n2p = 01. 
Study period versus post-study 
Relative to number of cigarettes used over the study period, self-reported number 
of cigarettes at post-study held steady for the control group, decreased for the CDMI only 
group, and increased for the CDMI plus CM participants. A non-significant trend was 
found at the;? < .30 level, F(2,33) = 1.30,/? = .28, n2 =.07, so effect sizes were calculated. 
A small to moderate effect was found when the control group was compared to CDMI 
only (d = .35), with the CDMI only group showing a continued decrease. A small to 
moderate effect was also found when the control group was compared to CDMI plus CM 
(d= .29), with the CDMI plus CM group showing an increase in number of cigarettes 
smoked at follow-up. The increase in the use of cigarettes for the CDMI plus CM group 
and the decrease for the CDMI only group resulted in a large effect when these two 
groups were compared (d = .96). 
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Relationship between biological and self-report measures 
Correlations were run between the biological measures (i.e., breath CO and saliva 
cotinine) and the self-reported number of cigarettes smoked. Regarding the relationship 
between saliva cotinine and average breath CO reading, a significant correlation was 
found for Week 3 (r = .41,/? = 01), Week 4 (r = 36,p = .03), and Follow-up (r=Al,p = 
.02). No significant relationship was found for Baseline through Week 2. 
With respect to saliva cotinine levels and number of self-reported cigarettes 
smoked, only a significant correlation was found for Week 1 (r = .36, p = .03). Number 
of cigarettes smoked was, however, significantly correlated with breath CO at Baseline (r 
= .46, p < .01), Week 1 (r = .43, p < .01), and Week 3 (r = .35, p = .03). No other 
significant relationships were found. 
These results suggest that the biological and self-report measures were reasonably 
associated. Average breath CO readings appeared to best correlate with both saliva 
cotinine levels and number of self-reported cigarettes smoked. 
Motivation to quit - VAS ratings 
Across all participants, the average motivation ratings were in the moderate range 
(range = 61.3 - 66.5; possible range 0-100). CDMI only participants showed an increase 
in motivation that peaked at Week 2 and was still elevated relative to baseline at follow-
up (Figure 10). CDMI plus CM participants showed some decreases in motivation, which 
were lowest at Week 3 but had returned to baseline levels at follow-up. Control 
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Baseline Week 1 Week 2 Week 3 Week 4 Follow-
up 
Figure 10. Average VAS motivation to quit smoking ratings for each week of the study 
plus follow-up. 
Summary of motivation rating findings 
Effect sizes suggest that during the study period, CDMI only participants had 
much higher levels of motivation than CDMI plus CM and control participants (who 
evidenced the lowest levels of motivation). There were no significant differences between 
the groups at follow-up. 
During treatment repeated measures 
Statistical analysis of these values (repeated measures ANCOVA with baseline 
motivation as the covariate) found a non-significant trend towards a main effect of group, 
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F(2,33) = 2.99,;? = .06, TI2P -.15. No main effect of time, F(5,363) = 1.09,/? = 37, r\\ 
=.03, or a time by group interaction, F(9, 363) = .75, p = .66, n2p =.04, were found. 
Further analyses were conducted due to the group effect/? value being well under 
the cut-off of < .30. These analyses (Fisher's LSD post-hoc) on the group main effect 
found no significant differences: Control and CDMI only (Mean Difference = 12.83,/? = 
.11); control and CDMI plus CM (Mean Difference = 3.98,p = .60); and CDMI plus CM 
and CDMI only (Mean Difference = 8.84,/? = .28). 
Two group comparisons were run and Cohen's d was calculated from partial eta-
squared. Very large effects were found when the CDMI only group was compared to the 
control (d = -.90) and CDMI plus CM group (d = -1.35), with the CDMI only group 
endorsing higher ratings than the other groups. A moderate effect was found between the 
control and CDMI plus CM groups (d = .46), with the control group endorsing the lowest 
ratings of motivation across the study period. 
Baseline versus post-treatment 
Change scores on average motivation ratings during Week 4 (minus baseline 
ratings) were not significantly different between the groups, F(2,34) = .99,/? = .38, r|2p 
= 39. 
Baseline versus follow-up 
Change scores were also calculated for the follow-up motivation ratings, minus 
ratings at baseline. Statistical analysis revealed no significant group differences, F(2,32) 
= .66,/?=.52,n2p = 04. 
Confidence in ability to quit - VAS ratings 
Across all participants, the overall confidence in ability to quit smoking ratings 
were relatively flat across the entire study period. The average rating was in the moderate 
range for each of the four weeks of the study plus baseline (range = 64.8 - 66.7; possible 
range = 1-100) and did not show a large degree of variation. This suggests that the 
average participant had a moderate degree of confidence that they could quit smoking 
across the study period. 
Separate analysis of the three different study groups revealed that the control 
group showed relatively flat ratings across time while the CDMI only group showed a 
sharp increase from baseline to Week 2 that leveled off in Weeks 3 and 4 (Figure 11). 
The CDMI and CM group had similar ratings at baseline and Week 4, although their 
lowest confidence ratings were in Week 3. At follow-up, the control and CDMI plus CM 
groups had relatively unchanged confidence ratings compared to baseline. The 
confidence ratings for the CDMI only group increased slightly from baseline to follow-
up, but were down from post-study levels. 
Summary of confidence in ability to quit smoking findings 
There was a significant group difference in confidence ratings across the study 
period, with CDMI endorsing the highest levels of confidence and the control group 
endorsing the lowest. Effect size estimates revealed a similar pattern of results when post-



















CDMI plus CM 
Figure 11. Average VAS confidence in ability to quit smoking ratings for each week of 
the study plus follow-up. 
During treatment repeated measures 
Linear analysis of these patterns (using a repeated measures ANCOVA with 
baseline confidence as the covariate) revealed a significant main effect of group, F(2,32) 
= 3.59, p =.04, r|2p =.18. No main effect of time, F(8, 352) = .63,;? =.74, n
2
p =.02, or time 
by group interaction, F(\6, 352) = 1.21,p =.26, TJ P =.07, were found. 
Post-hoc analyses (Fisher's LSD) on the group main effect found no significant 
differences: Control and CDMI only (Mean Difference = 1617.56,;? = .12); Control and 
CDMI plus CM (Mean Difference = 361.60, p = .72); and CDMI plus CM and CDMI 
only (Mean Difference = 1255.96,;? = .25). 
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Two group comparisons were run and partial eta-squared values were used to 
calculate Cohen's d. Very large effects were found when the CDMI only group was 
compared to the control (d= 1.01) and CDMI plus CM groups (d= 1.30), with the CDMI 
only group endorsing higher levels of confidence across the study period. Only a small to 
moderate effect was found when the control and CDMI plus CM group was compared (d 
- .35), with the control group showing slightly lower confidence ratings. 
Baseline versus Post-treatment 
To further examine any group differences over the study period, change scores 
were calculated for Week 4 values minus baseline confidence ratings. A non-significiant 
trend (at the p < .30 level) was found, F(2,34) = 1.92,/? - .16, n2p =.10. Effect size 
calculations revealed that the control and CDMI plus CM groups had similar small 
decreases in confidence across the study period (d = .10). The increase in confidence 
shown by the CDMI only group produced a large effect relative to the control (d = .74) 
and CDMI plus CM conditions (d = .80). 
Baseline versus follow-up 
Change scores were also calculated from baseline to follow-up for the confidence 
ratings. A univariate ANOVA was run and no significant difference between the groups 
was found, F(2,32) - .57,p = .57, n2p =.03. 
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Negative Effects of Smoking Questionnaire 
The overall ratings on the Negative Effects of Smoking Questionnaire remained 
relatively steady over time and did not show much variation (range = 25.6 - 27.6; 
possible range = 0-60). These values indicate that the average participant endorsed a 
moderate degree of negative effects from their smoking (Figure 12). When each group 
was examined separately, a divergent pattern of results emerged. At baseline, CDMI only 
participants endorsed more negative effects of their smoking than the CDMI plus CM 
group (this measure was not administered to control participants at baseline). At post-
study and follow-up, the CDMI only group slightly increased the number of negative 
effects that they endorsed, while the CDMI plus CM group endorsed fewer negative 
effects relative to CDMI only and relative to their own baseline. The control group scores 
fell between the other two groups at post-study and follow-up. 
Cronbach's alpha was run to test for internal consistency of this measure. Alpha 
levels were .92 at baseline, .90 at post-test, and .90 at follow-up. 
Summary of negative effects of smoking results 
Significant differences were found between the CDMI only and CDMI plus CM 
groups, with the CDMI only participants endorsing significantly more negative effects of 
smoking at post-study and follow-up, relative to baseline. 
Baseline versus post-study 
Change scores were calculated for the difference between baseline and post-study. 







- • - Control 
- • -CDMI only 
- * - CDMI plus CM 
Baseline Post-study Follow-up 
Figure 12. Total scores on the Negative Effects of Smoking Questionnaire at baseline, 
post-study, and follow-up 
at baseline. A univariate ANOVA revealed a significant group difference, F(l,21) = 4.76, 
p = .04, n2p=. 19. Effect size calculations revealed that this was a large effect for the 
comparison between CDMI plus CM and CDMI only (d = -.93), with the CDMI only 
group showing an increase in their total score over time. The number of negative effects 
endorsed by the CDMI only group increased over the study period, while they decreased 
for the CDMI plus CM group. 
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Baseline versus follow-up 
Change scores from baseline to follow-up were also calculated for the CDMI only 
and CDMI plus CM groups. These change scores were found to be significantly different 
between the two groups, F(\,2\) = 5.91,p = .02, r\2p =22. Effect size calculations 
indicated that the magnitude of the difference between the groups was large (d= 1.03), 
with the CDMI only group endorsing more negative effects. 
Motivation for Change Questionnaire 
Internal Motivation Subscale 
The Motivation for Change Questionnaire was administered only at post-study. 
Analysis of the internal motivation subscale showed that the groups were virtually the 
same on their average score and all showed a relatively high degree of internal motivation 
(M= 18.6; possible range 0-25). This similarity was confirmed with a univariate 
ANOVA, F(2,34) = .03,p = .98, n2p = .00 (Table 4). Cronbach's alpha indicated that the 
internal subscale had an acceptable level of internal consistency, with an alpha level of 
.79. 
Summary of results for the motivation for change subscale 
Effect size estimates suggest that the CDMI plus CM group endorsed the highest 
levels of external motivation, while the CDMI only group endorsed the lowest levels. No 
difference was found between the three groups on the internal motivation subscale. 
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Table 4 
Motivation for Change Questionnaire subscale scores. 
Control CDMI only CDMI plus CM 
Mean (SD) Mean (SD) Mean (SD) 
Internal subscale 18.7(5.1) 18.8(4.4) 18.4(3.6) 
External subscale 11.6(3.9) 11.0(2.0) 13.2(2.9) 
External Motivation Subscale 
The external motivation subscale scores were considerably lower across all 
groups than the internal motivation scores. Across all participants, a moderate degree of 
external motivation was endorsed (M = 11.9; possible range 0-25). The CDMI only group 
endorsed the lowest degree of external motivation while the CDMI plus CM group 
endorsed the highest. 
A test of internal consistency indicated that the external subscale had a low 
Cronbach's alpha value of .41. 
Statistical analysis revealed a non-significant trend (at the/? <.30 level) between 
the groups, F(2,34) = 1.66,/? = .21, n p = .09. Exploratory effect size calculations showed 
a small to moderate effect size between the control and CDMI only group (d = -.42), with 
the CDMI group scoring lower on external motivation than the control. There was a 
moderate to large effect size for the comparison between the control and CDMI plus CM 
group {d - .72), with the CDMI plus CM group endorsing more external motivation. This 
magnitude of effect was largest for the CDMI only and CDMI plus CM group (d= 1.01). 
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Treatment Self-Regulation Questionnaire 
Summary of treatment self-regulation questionnaire findings 
Effect sizes estimates suggest that the CDMI plus CM group endorsed the highest 
level of amotivation, while the CDMI only group endorsed the lowest level. No group 
differences were found on the autonomous or controlled subscales. 
Autonomous Subscale 
Overall, the participants had relatively high ratings on the autonomous subscale 
(M= 5.8; possible range 1-7), indicating that they felt a large degree of autonomy. No 
significant differences were found between the groups, F(2,33) = .08,/? = .92, r\ p = .01 
(Table 5). Cronbach's alpha was .81 for this subscale, indicating an acceptable level of 
internal consistency. 
Table 5 
Treatment Self-Regulation Questionnaire subscale scores 
Control CDMI only CDMI plus CM 















Across all participants, ratings on the controlled subscale were in the moderate 
range (M= 3.1; possible range = 1-7) at post-study, indicating that participants felt a 
moderate degree of control was being exerted over them. No significant difference 
between the groups was found on this subscale, F(2,33) = .56, p - .57, r| p = .03. There 
was found to be a large degree of internal consistency for this subscale (Cronbach's alpha 
of .82). 
Amotivated Subscale 
At post-study, the average amotivated subscale score across all participants was 
found to be in the low to moderate range (M- 2.7; possible range = 1-7), indicating that 
the average participant felt a moderate degree of amotivation (i.e., a lack of motivation). 
Cronbach's alpha was found to be quite low for this subscale (.20). A univariate ANOVA 
found a non-significant trend towards a difference between the groups on this subscale, 
F(2,33) = 2.74, p = .08, n2p = .14. Because this trend was well under the p < .30 cut-off, 
post-hoc analyses were done. These analyses (Fisher's LSD post-hoc) revealed a 
significant difference on this variable between the CDMI only and CDMI plus CM group, 
with the CDMI plus CM group endorsing more amotivation than the CDMI only group 
(Mean Difference = 1.12,/? = .03). Control group amotivation ratings fell between the 
other two groups but were not significantly different from either. 
Effect size estimates showed large effects when the CDMI plus CM group scores 
were compared to the control (d = -.84) and CDMI only groups (d = -1.00), with the 
CDMI plus CM group having the highest amotivation score. A moderate effect was found 
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when the control and CDMI only groups were compared (d= .58), with the control group 
having the higher amotivation score. 
Attributes of Treatment Questionnaire 
As shown in Table 6, the overall rating of satisfaction with the various 
interventions across all three study groups was relatively high (M= 3.94, SD = .39; 
possible range 1-5). A test of internal consistency revealed a Cronbach's alpha value of 
.65. An analysis between the groups revealed no significant difference, F(2,34) = .36,p = 
.70, n2p = .02. 
Table 6 
Attributes of Treatment Questionnaire scores at post-study 
Control CDMI only CDMI plus CM 
Mean (SD) Mean (SD) Mean (SD) 
Attributes of Treatment 
Total Score 3.88 (.47) 4.01 (.42) 3.93 (.26) 
Chapter IV 
DISCUSSION 
Overview of main findings 
This exploratory/developmental study was intended to allow examination of 
patterns of effects, in order to inform subsequent and more fully powered trials. In such 
research, the hope is that effects of at least moderate magnitude will be obtained, with 
statistical significance being a less crucial—but still desirable—secondary goal. Many 
interesting effects of moderate magnitude and greater were observed, some of which 
reached statistical significance. This study was therefore highly successful in reaching the 
above goal. 
Overall results suggest that both CDMI only and CDMI plus CM may lead to 
positive effects with respect to smoking and smoking-related variables. However, there 
were clear differences in the kinds of outcomes for which each intervention appeared 
best. Participants in the CDMI plus CM group showed the greatest reductions in breath 
CO over the course of the study period. These reductions reached statistical significance 
for some analyses. In contrast, the CDMI only intervention was associated with better 
outcomes in terms of several motivation-related variables. Therefore, it appears that the 
combination of an intervention aimed at increasing internal motivation (CDMI) with an 
intervention that involves a high degree of external motivation (CM) interferes with the 
internalization of motivation yet exerts a powerful influence on behaviour change, at least 
in the short term. 
71 
Changes in smoking behaviour 
With respect to the changes in smoking behaviour, results are mixed. As 
mentioned above, the breath CO readings for the CDMI plus CM participants were the 
lowest of the three groups across the study period. That is, the combination of CDMI and 
CM was most efficacious in producing reductions in smoking behaviour, as measured by 
breath CO. CDMI alone was more efficacious than control. The analysis of this data 
closely approached statistical significance and reached the level of significance in one 
instance. These differential effects were only present while the interventions were in 
place, as no differences were found at five-week follow-up. 
These breath CO findings are inconsistent with the number of cigarettes 
participants reported smoking, although these two measures were found to be 
significantly correlated at half of the time points. All three study groups reported 
equivalent reductions in number of cigarettes smoked during the study period. The fact 
that even control participants greatly reduced their level of smoking is consistent with 
other studies of substance abuse interventions, in which participation in baseline 
assessment is often associated with substantial reductions in use (e.g., Epstein, Drapkin, 
Yusko, Cook, McCrady, & Jensen, 2005). 
The findings at follow-up with respect to number of cigarettes smoked suggest 
some differential intervention effects. While all three groups maintained their reductions 
relative to baseline, there was some evidence to suggest that the CDMI only group 
continued to reduce their levels of smoking relative to the study period. In contrast, the 
CDMI plus CM group had increased their levels of self-reported cigarette use relative to 
the study period. This finding is consistent with study hypotheses and previous studies of 
CM, which typically find increases in target behaviour when the contingencies are 
removed (e.g., Hey & Perera, 2006b; Prendergast et al., 2006). 
The above findings for breath CO and number of cigarettes smoked are also 
inconsistent with levels of saliva cotinine. Saliva cotinine was found to be moderately 
associated with breath CO levels, but poorly related to number of cigarettes smoked. This 
measure found no difference in cotinine levels across time or between the three study 
groups. As these cotinine tests have been found to have an excellent level of specificity 
and sensitivity (Cooke et al., 2008), it must remain a possibility that there were no 
smoking-related reductions produced by either of the two interventions, relative to 
control. 
The difference in findings between the two biological measures (breath CO and 
saliva cotinine) merits attention. The primary difference between these measures is that 
breath CO is under more participant control than saliva cotinine. That is, level of saliva 
cotinine remains more constant in the body than breath CO, which will begin to decrease 
soon after a cigarette has been smoked. It is therefore possible that participants learned to 
alter their smoking habits so that their breath CO was reduced at the time of testing (i.e., 
refraining from smoking prior to providing a breath CO sample). This explanation is 
consistent with the finding that although breath CO was lowest for the CDMI plus CM 
group, the number of cigarettes smoked across the study period was reduced to a similar 
degree by each of the groups. Saliva cotinine readings (which would be less affected by 
minor alterations in one's pattern of smoking) did not show differential changes over the 
study period. It is therefore possible that CDMI plus CM participants learned to modify 
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their smoking in an attempt to obtain contingency payments by providing samples below 
the set cut-offs. 
This hypothesis is consistent with anecdotal reports from a CDMI plus CM 
participant who frequently earned CM payments by providing a breath sample in the non-
smoker range. This individual reported to the investigator on several occasions that her 
reduced breath CO samples were due to the fact that she had reduced her overall smoking 
levels but had also changed her smoking pattern, such that she did not smoke for the 12 
hours prior to testing. 
If this explanation is true, it suggests that the reductions in breath CO shown by 
the CDMI plus CM participants may not reflect true reductions in smoking. The effects 
seen in the control and CDMI only group should not be affected by this hypothesis, as 
their level of breath CO had no impact on payments that they received for simply 
providing a sample. Some CM studies require participants to provide breath CO samples 
more than once a day, and a more frequent sampling schedule may help address this issue 
in future research. 
The possibility must also be acknowledged that relationship with the researcher, 
even in the context of a formalized research protocol, may have contributed to the 
changes observed in the CDMI and CM group. That is, an interpersonal aspect of 
reinforcement (e.g., acknowledgement by another of smoking-related changes) outside of 
the CM payments may have accounted for some degree of change in this condition. 
While being mindful of the above possible explanations for the results, these 
findings suggest that CDMI plus CM was most effective in reducing smoking during the 
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study period (as measured by breath CO), while CDMI only was most effective at 
reducing smoking at five-week follow-up (as measured by number of cigarettes smoked). 
Changes in motivation 
Across the study period, participants who received only the CDMI were found to 
be highest on visual analogue scale measures of motivation to quit smoking. There were 
no differential effects between the groups on motivation to change at follow-up. This was 
partly consistent with hypotheses, which predicted a better motivation outcome for CDMI 
participants at post-study and follow-up. CDMI only participants were also found to 
endorse the most negative effects related to their smoking. Developing an awareness of 
positive and negative aspects of behaviour change is a key component of MI and may 
also be taken as a possible indicator of growing motivation to change smoking behaviour. 
There is further indication that the combination of CDMI plus CM impacted 
motivation relative to CDMI alone. Specifically, the CDMI plus CM group endorsed the 
highest levels of external motivation and amotivation (i.e., lack of motivation) relative to 
the other two groups. 
Therefore, while CDMI only participants endorsed the most motivation to change, 
participants who also received the CM appeared to be externally motivated. Although the 
effects of CDMI and CM cannot be teased apart, it can be hypothesized that the CM 
overshadowed the CDMI for these participants and interfered with the internalization of 
motivation to change. However, it is also worth noting that motivation to change is a 
highly reactive variable that is responsive to changes in the target behaviour (in this case, 
smoking). For example, someone who has successfully quit may endorse less motivation 
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or need to change, because he or she has already done so. It is therefore possible that the 
CDMI plus CM condition appears less motivated to quit smoking simply because they 
had actually reduced their levels of smoking to the largest degree. This suggestion is 
supported by the increase in motivation seen in this group from post-treatment to follow-
up, during which time their level of smoking appears to have increased. 
It is also important to note that while there was a difference between the groups 
on level of external motivation, there was no difference on level of internal motivation 
(as measured by the Motivation for Change Questionnaire). This is inconsistent with 
hypotheses based on the SDT and is in contrast to the visual analogue scale (VAS) 
ratings of motivation, on which the CDMI only participants rated themselves as most 
motivated. This VAS was less specific about the source of motivation (i.e., "How 
motivated are you to quit smoking"). While it can be assumed that this is capturing 
internal motivation, these results should be interpreted with some caution. 
Implications of findings and potential limitations 
These findings suggest that low-intensity CM may have positive effects on 
cigarette smoking (as measured by breath CO) while the contingencies are in place. This 
has important implications for more widespread use of such an intervention, as the cost of 
such programs is often a barrier to implementation. In this study participants in the CM 
group were offered the opportunity to earn $81 to stop smoking (the average actually 
earned by participants was $16). Even at this low level of potential payment, a significant 
reduction in breath CO was found over the study period. 
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While the combination of CDMI and CM produced reduced breath CO over the 
study period, CDMI alone was the most effective intervention at reducing number of 
cigarettes smoked at five-week follow-up. This condition also produced the highest level 
of motivation for change. The combination of CDMI and CM produced reductions in 
breath CO but was more costly to run and did not show reductions in number of 
cigarettes smoked at follow-up relative to the control condition. Due to the more lasting 
effects and low cost to implement, the CDMI on its own offers clear advantages to the 
combined approach of both CDMI and CM. 
These findings also suggest that if harm reduction is a desired outcome of 
treatment, simple monitoring of cigarette use may be enough to affect some degree of 
change. Although control participants did not show the same degree of breath CO 
reductions and motivation to change evidenced by the intervention groups, it appears that 
frequent monitoring of cigarette use or other study-related factors in the absence of direct 
intervention led to decreases in self-reported number of cigarettes smoked. These 
decreases in cigarette use were comparable to those reported by the intervention groups 
and represent a decrease of approximately three cigarettes per day relative to pre-study. 
In fact, these overall reductions across all participants were larger than the between-group 
differences. Furthermore, these reductions were maintained in the control group even at 
five-week follow-up. 
Previous studies would suggest that it is not only the frequency of assessment that 
leads to changes in the control condition, but any assessment at all. It has been found that 
even brief baseline assessment is often enough to lead to changes in behaviour. Among 
the hypothesized reasons for these pre-treatment changes are the provision of 
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information, natural change as the result of self-observation, and elicitation of personal 
concerns and reasons for change (Epstein et al., 2005). 
In a study of women seeking treatment for alcohol abuse or dependence, Epstein 
et al. (2005) found that significant reductions in drinking occurred during each stage of 
the pretreatment assessment. As a result, 44% of participants reported becoming abstinent 
prior to entering treatment. Kypri, Langley, Saunders, and Cashell-Smith (2007) have 
also demonstrated an assessment effect with lasting impact. Relative to an information-
only group, individuals given information and a ten minute assessment of their alcohol 
use reported significantly lower consumption and alcohol-related problems at 12-month 
follow-up. 
The impact of this pre-treatment change is that it decreases the chances of finding 
differential treatment outcomes and must be acknowledged as a potential limitation in the 
present study. It is possible that limiting the length and frequency of assessment in the 
control condition may have led to larger effects. 
How does this build on previous research? 
The findings from this study are somewhat consistent with previous studies. 
Specifically, Budney et al. (2000) found that a group that received motivational 
intervention, behavioural skills coping, and CM had greatest reductions in marijuana use 
across the study period. This is consistent with our findings that the combination of 
motivational intervention and CM produced the greatest reductions in smoking (as 
measured by breath CO) while the interventions were in place. Kadden et al. (2007) also 
found that the two groups that received CM had the best outcomes during the study 
period. However, the combination of motivational enhancement, cognitive behaviour 
therapy, and CM produced the greatest degree of marijuana abstinence at follow-up. This 
suggests that either the cognitive behavioural therapy or motivational enhancement may 
have had a delayed effect that was not realized until the follow-up period. The results of 
this study, coupled with SDT, would suggest that the motivational enhancement 
component may have produced these reductions in marijuana use at follow-up. This is in 
contrast with a study that targeted cocaine use in methadone maintained individuals 
(Epstein, Hawkins, Covi, Umbricht, & Preston, 2003). While CM alone produced initial 
reductions in cocaine use while the contingencies were in place, at 12-month follow-up it 
was the combination of CM and cognitive behaviour therapy that produced the greatest 
reductions. Epstein et al. (2003) hypothesized that the late gains in the CM and cognitive 
behaviour therapy group were the result of a gradual process of learning that took place 
with the cognitive behavioural component. The exact mechanisms of this delayed effect 
remain unknown, but it is evident that motivational intervention may result in a similar 
"sleeper" effect. 
With respect to our finding that the combination of motivational intervention and 
CM may have interfered with the internalization of motivation to change, motivation was 
not assessed by Kadden et al. (2007). Budney et al. (2000) found that self-reported 
motivation decreased for all three groups across the study period, and was in fact lowest 
for the group receiving motivational enhancement. 
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How do the results fit with the self-determination theory? 
The results of this research appear to support the SDT and suggest that the two 
interventions (CDMI and CM) fall on opposite poles of the continuum of autonomy. That 
is, the combination of CDMI and CM (which led to high levels of external motivation) 
effectively reduced breath CO while the intervention was in place but increases in 
number of cigarettes smoked were evident at follow-up. This is consistent with behaviour 
towards the amotivated end of the continuum. This was confirmed by the higher ratings 
of amotivation evidenced in the CDMI plus CM group. 
In contrast, the CDMI alone produced more lasting changes. This is more 
consistent with behaviour at the intrinsic regulation end of the spectrum. Furthermore, the 
results obtained from the combined intervention group (CDMI plus CM) are consistent 
with the results of Deci (1971) who found that external rewards interfere with the 
internalization of motivation. This is evident in the way in which CDMI plus CM 
participants differentiated themselves from CDMI only participants by showing 
continued reductions in cigarette use only when the intervention was in place. 
Research related to the SDT has found that amotivation is associated with poor 
treatment outcomes (Senecal, Nouwen, & White, 2000). This is somewhat consistent 
with the results of this study, in which the CDMI plus CM group endorsed significantly 
higher levels of amotivation than either CDMI or control. It is possible that participants 
in this condition acknowledged the shorter term benefits of this treatment (i.e., contingent 
reinforcement), but did not view it as a method of supporting longer term goals (e.g., 
quitting smoking). 
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The results are also consistent with SDT, in that this theory would suggest that 
behaviour change might occur at different times for the CDMI plus CM and CDMI only 
groups. That is, according to SDT, CDMI plus CM participants should evidence more 
immediate changes in behaviour, while behaviour change may occur over a more 
extended period of time in the CDMI only group, as motivation for change builds. This 
appears to be the pattern in the present study, in that changes for the CDMI group were 
slower to appear, but also extended past the intervention period. It may be that longer 
follow-ups would capture continued decreases in smoking behaviour for this CDMI only 
group. 
What does this tell us about computerized approaches to motivational intervention? 
One goal of this research was to assess the efficacy of a brief computerized 
motivational intervention in affecting smoking-related behaviour change. Affecting 
change in smoking behaviour is traditionally quite difficult regardless of the intervention 
used (Lancaster & Stead, 2006a). With respect to traditional motivational interventions, 
meta-analyses suggest that the effect size for such interventions relative to no 
treatment/placebo ranges from .11 (Burke et al., 2003; Burke et al., 2004) to .14 (Hettema 
et al., 2005). Over this five-week study, the key measures found intervention effects for 
control relative to CDMI of .23 for saliva cotinine, .44 for number of cigarettes smoked, 
.52 for breath CO, and .90 for motivation to quit. In all cases, CDMI demonstrated more 
favorable outcomes than control. These results suggest that this computerized 
intervention (in which changes in smoking behaviour, rather than complete abstinence 
was assessed) was more efficacious at producing behaviour change over the course of the 
81 
study than previous research examining traditional MI for smoking cessation. These 
effects are on par with the general effects associated with motivation interviewing 
relative to control across all areas of behaviour change (i.e., .36 to .56; Burke et al., 
2004). 
While the CDMI was efficacious at producing changes in smoking behaviour and 
motivation, acceptability must also be considered. Although the ratings of response to 
treatment received were not significantly higher than the other two groups, participants 
who received the CDMI rated the intervention in positive ways such as helpful, 
understanding, supportive, enjoyable, respectful, and as something that made them want 
to change. They also endorsed the intervention as something they would recommend to 
others. These positive ratings are consistent with previous studies of similar computerized 
interventions (Ondersma et al., 2005; Ondersma et al., 2007) that found participants gave 
high ratings of approval to the intervention. 
These results suggest that computerized interventions are well accepted by 
consumers and may produce smoking-related behaviour change that is more stable in the 
longer-term, than more expensive and time-consuming traditionally delivered 
motivational interventions. 
Directions for future research 
The results of this small sample, exploratory study suggest many different areas 
for future exploration. Based on the promising and intriguing results of this research, it is 
clear that larger scale studies of this kind are needed. Specific suggestions are discussed 
below. First, initial studies further exploring the combined efficacy of CM and CDMI 
82 
may wish to use larger contingency payments in order to more clearly differentiate 
treatment effects. While the relatively small payments used in this study (maximum 
payment of $81) were effective at producing changes in smoking behaviour, research has 
shown that lower magnitude incentives produce smaller degrees of change than higher 
magnitude incentives (but more than no incentives at all); (Silverman, Chutuape, 
Bigelow, & Stitzer, 1999). In order to maximize any differential treatment effects and 
increase the odds of statistical significance, larger contingency payments may be well-
advised. Longer-term research, however, may wish to focus on smaller contingencies, as 
any level of monetary payment is a significant barrier to implementation in most 
community or hospital settings. Recent research has pursued such contingencies as the 
opportunity to win prizes (e.g., Alessi, Hanson, Wieners, & Petry, 2007; Olmstead, 
Sindelar, & Petry, 2007). This option has shown itself to be both cost-effective and 
efficacious at producing behaviour change. 
An even more intriguing option regarding contingency payments is to examine if 
there are contingencies that are efficacious at reducing smoking behaviour but will not 
interfere with the internalization of motivation. Non-monetary rewards such as paid job 
training (Silverman, Svikis, Robles, Stitzer, & Bigelow, 2001) and access to subsidized 
housing (Schumacher et al., 1999) have previously been used as effective contingencies 
in reducing substance abuse. There may also be methods of framing external incentives 
(e.g., as a participant-chosen means of supporting their own change goals). These 
possibilities suggest that not all CM may be associated with amotivation, as was found in 
the present study. By giving individuals a choice of contingencies and input on whether 
this is the best method to help them reach their goals, it may be possible to foster 
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autonomy with this approach. The impact of varying types of rewards on motivation 
should also be more fully explored, as it may be that different types of contingencies are 
complementary to motivational interventions. 
Future researchers may also wish to manipulate the timing of the CDMI and CM 
in relation to each other. For example, it may be beneficial to expose participants in the 
combined condition to each intervention but not allow the interventions to overlap. In 
particular, it may be worth examining whether a CM period followed by a CDMI 
intervention upon termination may be more effective than applying both interventions at 
once. These results suggest that the CM will produce reductions in smoking behaviour 
that may lead to an experience of competence. This sense of competence is felt to be a 
key condition to enhance autonomous motivation (Deci & Ryan, 1985). Therefore, it may 
be possible that the later introduction of the CDMI may present an opportunity to build 
on smoking reductions produced by the CM. This may lead to a greater ability to 
internalize motivation, and therefore more lasting treatment outcomes. Similarly, it may 
also be desirable to wean participants off of CM by reducing the incentives over time. 
This may also allow for participants to build on their smoking reductions from the CM 
and internalize their motivation to change as the CM incentives are decreased. An 
additional point to consider is the apparent plateau in motivation level that the CDMI 
only group evidenced beginning at Week 2. Future research should explore whether a 
smaller interval of time between CDMI sessions (approximately four weeks in the current 
study) would be more optimal in fostering continued motivation. 
Additional methodological changes worth pursuing include the inclusion of a CM 
only group. While not feasible in the present study because of budget constraints and a 
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small sample size, a four group design (i.e., control, CDMI only, CM only, CDMI plus 
CM) might help to more clearly understand the combined intervention group. It was 
impossible to tease apart the differential effects of the two interventions in the CDMI and 
CM group, and a CM only condition might serve as a useful comparison to help further 
determine any potential benefits of the combined intervention. 
Another methodological consideration involves incorporating more follow-up 
time points. There is some indication from these findings that the effects of the CDMI 
may be appear more slowly, as there were apparently continued positive effects on 
number of cigarettes smoked between post-study and five-week follow-up for the CDMI 
only group. It would be helpful to obtain more information about this. Additionally, at 
five-week follow-up all three study groups self-reported smoking significantly fewer 
cigarettes than at baseline. More longer-term follow-up would help determine if and 
when smoking returns to baseline levels. 
The results of this small sample exploratory study are useful in providing 
preliminary ways of thinking about the effects of an intervention combining both internal 
and external motives for smoking-related behaviour change. It is likely that these 
mechanisms of change interact in highly complex ways, and further research is needed to 
build on and expand these findings. 
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1. Gender: Male Female 
2. Age: 
3. Ethnicity: African American Caucasian Other 
4. Please circle ALL the days that you currently dose at the clinic: 
MON TUES WED THURS FRI SAT 
5. Are you currently taking the medications BUPROPION. WELLBUTRIN or 
ZYBAN ? 
Yes No 
6. How many cigarettes per day do you smoke on average? 
APPENDIX D 
Study Costs 






Breath CO payments (regular) 
















Smokerlyzer mouthpieces $375.90 TOTAL: $4018.08 
Miscellaneous: 
Supplies, etc. $131.69 TOTAL: $387.79 
TOTAL GRANT EXPENSES: $7910.87 
APPENDIX E 
Informed Consent for Study Participation 
Research Informed Consent 
Title of Study: 
Computerized motivational intervention and contingency management for 
tobacco smoking in methadone-maintained opiate-dependent individuals 
You are being asked to be in a research study of ways to help people who may 
want to quit smoking. The study is being conducted at the Jefferson Avenue 
Research Clinic, which is affiliated with Wayne State University. Please read this 
form and ask any questions you may have before agreeing to be in the study. 
The study is being conducted by Heather Durdle, MA, of the Department of 
Psychology, University of Windsor and Steven Ondersma, PhD, of Wayne State 
University.The funding for this study is being provided by the Canadian Tobacco 
Control Research Initiative. 
Study Purpose: 
The purpose of the study is to understand how your smoking behavior changes 
over time. The estimated number of study participants to be enrolled at Wayne 
State University is about 60. 
Study Procedures: 
Participants in this study will be divided into three different groups. The general 
procedure for each of these groups is the same. If you take part in the study, you 
will be asked to do the following: 
You will be asked to complete some initial questionnaires. These will include 
questions about yourself and questions related to your use of cigarettes. 
Throughout the study, you are free to choose not to answer any of the questions 
that are asked of you. These initial questionnaires should take about 20 minutes 
of your time and will be completed on an easy-to-use talking computer. You do 
not need to know how to use a computer to do any of the computer tasks in this 
study. 
For the next five weeks, the researcher will meet with you when you come into 
the clinic on Monday, Wednesday, and Friday. You will be asked to answer a few 
short questions about your use of cigarettes each time. You will also be asked to 
provide a sample of your breath carbon monoxide on each of these days. This is 
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done by blowing into a cardboard mouthpiece attached to a small carbon 
monoxide detector. On one of these days each week (which will be chosen 
randomly), you will also be asked to provide a saliva sample. This is done by 
placing a small amount of oral fluid into a collection container. This breath 
sample and saliva sample will tell us if you have been smoking recently. 
Answering these questions and providing these samples should take about five 
minutes of your time on each visit. 
One week from now, we will ask you to complete a computer task. This will 
involve answering some questions and doing some activities that the computer 
asks of you. This should take about 20 minutes of your time. Approximately 
three weeks later, we will ask you to complete the computer task again. This 
should also take you about 20 minutes. 
On your last visit at the end of these five weeks, you will be asked to complete 
the same questionnaires that you did at the beginning of the study. This should 
take about 15 minutes of your time. 
Once the study has finished, the researcher will return to the clinic five weeks 
later. If you are still attending the clinic, the researcher will ask you to answer 
some questions about your use of cigarettes and provide a breath carbon 
monoxide sample. These visits should take 20 minutes of your time. 
At the beginning and end of the study period and at the follow-ups, the 
researcher will access your online medical records on the clinic database. The 
researcher will record the results of your urine drug screens that you provide as 
part of regular clinic procedures. The results of these urine drug screens will 
in no way affect your participation in this study. 
Benefits: 
There may be no direct benefits for you; however, information for this study may 
benefit other people now or in the future. The possible benefits to you for taking 
part in this study are that you may decrease the number of cigarettes that you 
smoke. Additionally, information from this study may help other people now or in 
the future by helping researchers design ways to help people who want to stop 
smoking. 
Risks: 
There may be some minimal risks associated with your participation in this study, 
including potential stress. The study investigator will also know about your recent 
use of nicotine or illicit substances, which may cause you some embarrassment 
or loss of privacy. 
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Alternatives: 
There are no alternative treatments to not participating in this study. If you 
choose not to participate in this research but would like to receive support for 
quitting smoking, the investigator can provide you with a list of resources. All 
people who enrol in this study will also receive this list of resources. 
Research Related Injuries: 
In the unlikely event that this research related activity results in an injury, no 
reimbursement, compensation or free medical care is offered by Wayne State 
University. 
If you think that you have suffered a research related injury, let the investigator know 
right away. 
Study Costs: 
There will be no costs to you for participation in this research study. 
Compensation: 
The amount and type of compensation that you receive will depend on what 
group you are randomly assigned to. The investigator will let you know on the 
first day of the study what group you are in. 
Throughout the study, each time you earn less than $5, you will receive 
McDonald's gift certificates. If the amount you earn is $5 or more, you will receive 
Target gift cards. 
Everyone participating in the study will be compensated in the following ways. 
• For completing the initial questionnaires, you will receive $5 in gift cards. 
• When you complete the two computer tasks, you will receive $10 in gift 
cards each time. 
• Once the study period is over, you will receive $5 in gift cards for 
completing the same questionnaires that you did at the beginning of the 
study. 
• For each follow-up that you participate in, you will receive $15 in gift cards. 
For providing breath and saliva samples, Group 1 and Group 2 will be 
compensated in the following way: 
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• Over the course of the five-week study, each time that you give us a 
sample of breath carbon monoxide and/or saliva and complete the brief 
smoking-related questionnaires, you will receive $2 in gift cards. 
For providing breath and saliva samples, Group 3 will be compensated in the 
following way: 
• For the first week of the study, each time that you give us a sample of 
breath carbon monoxide and/or saliva and complete the brief smoking-
related questionnaires, you will receive $2 in gift cards. 
For the last four weeks of the study, each time that give us a sample of 
breath carbon monoxide and/or saliva and complete the brief smoking-
related questionnaires, you will receive $1 in gift cards. You may also earn 
additional gift cards if the samples you provide indicate that you have not 
been smoking recently. Both your breath and saliva samples must 
show that you have not been smoking in order to earn this payment. 
During these four weeks, the first negative sample that you give us will 
earn you $4.00. For each time in a row that you give us negative samples, 
you will earn an extra 50 cents on top of your last payment. If you give us 
a sample that shows you have recently been smoking, you will not earn 
anything additional that day and the most you can earn the next day is 
reset to $4.00. 
If each part of the study is completed, Group 1 and Group 2 will receive a 
MAXIMUM of $75 in gift cards. If each part of the study is completed and a 
negative breath and saliva sample is provided on each day of the study, Group 3 
will earn a MAXIMUM of $141 in gift cards. 
Confidentiality: 
All information collected about you during the course of this study will be kept 
confidential to the extent permitted by law. You will be identified in the research 
records by a code name or number. A master list with your identifying information 
will be kept in a secured location. Information that identifies you personally will 
not be released without your written permission. However, the study sponsor, the 
Human Investigation Committee (HIC) at Wayne State University, the Research 
Ethics Board (REB) at the University of Windsor or federal agencies with 
appropriate regulatory oversight (e.g., Food and Drug Administration [FDA], 
Office for Human Research Protections [OHRP], Office of Civil Rights [OCR], 
etc.) may review your records. 
Any information that you provide (including the results of your breath or 
saliva samples) will NOT be shared with your counsellor or any other clinic 
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staff. You may, however, choose to tell your counsellor about your involvement 
in this study. 
A secured master list will match your participant identification number to your 
clinic ID. This is so the investigator can access information on your urine drug 
screens and other demographic information included in the clinic's computer 
system. Because your clinic ID contains your initials and the last four digits of 
your social security, you will be asked to complete a separate form to authorize 
the researcher to use this information to access the clinic database. Your name 
or clinic ID will not be associated with any of the information that you provide. 
Personal Health Information (PHI) used and disclosed for the purposes of this 
study is protected under the federal regulation know as HIPAA (Health Insurance 
Portability and Accountability Act). Your study investigator will discuss with you 
your rights under this federal regulation and obtain your authorization to allow the 
research team to access your PHI. 
Voluntary Participation /Withdrawal: 
Taking part in this study is voluntary. You may choose not to take part in this 
study, or if you decide to take part, you can change your mind later and withdraw 
from the study. You are free to not answer any questions or withdraw at any 
time. Your decision will not change any present or future relationships with 
Wayne State University or its affiliates or other services you are entitled to 
receive. 
Your participation in this study is in NO way associated with your 
methadone treatment. Although you will be asked to provide breath carbon 
monoxide and saliva samples throughout the course of the study, the results of 
these samples will not affect your treatment in any way. If you choose to 
withdraw from this study, this will not affect your enrolment in the clinic. 
Subsequent Use of Data: 
It is possible that the data from this research may be used in subsequent studies 
to answer a different research question. Your name or other identifying 
information will remain confidential. If you do not consent to the further use of 
your data, please initial here: 
Questions: 
If you have any questions now or in the future, or if you think that you need to 
report a research related injury, you may contact Dr. Steven Ondersma at (XXX) 
XXX-XXX or Heather Durdle at (XXX) XXX-XXX. If you have questions or 
concerns about your rights as a research participant, the Chair of the Human 
Investigation Committee can be contacted at (XXX) XXX-XXXX. 
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Consent to Participate in a Research Study: 
To voluntarily agree to take part in this study, you must sign on the line below. If 
you choose to take part in this study, you may withdraw at any time. You are not 
giving up any of your legal rights by signing this form. Your signature below 
indicates that you have read or had read to you this entire consent form, 
including the risks and benefits, and have had all of your questions answered. 
You will be given a copy of this consent form. 
Signature of Participant/Legally Authorized Representative Date 
Printed Name of Participant/ Authorized Representative Time 
"Signature of Witness (When applicable) Date 
Printed Name of Witness Time 
Signature of Person Obtaining Consent Date 
Printed Name of Person Obtaining Consent Time 
APPENDIX F 
Quit Smoking Resources: 
The following are free smoking cessation resources that are available to you, 
should you choose to use them: 
Telephone Numbers: 
National Network of Tobacco Cessation Quitlines: 
1-800-QUIT-NOW 
1-800-784-8669 
American Cancer Society Quitline: 
1-800-ACS-2345 
American Lung Association: 
1-800-LUNG-USA 
Websites: 
American Cancer Society: 
www.cancer.org 
Click on "Guide to quitting smoking" 
American Lung Association: 
www.lungusa.org 
Click on "Tobacco control" 
American Heart Association: 
www.americanheart.org 
Search for "Smoking" 
Baseline Weekl 
APPENDIX G 
Timeline of Study - Payment Schedule 





Breath CO and 
Tobacco Use and 





Control and CDMI 
Groups: 
Breath CO and 
Tobacco Use and 
Beliefs on 
M/W/F ($2) 
CDMI + CM Group: 
Same as above with 
payment contingent 
on breath CO/saliva 
cotinine level 
(plus $1) 
Control and CDMI 
Groups: 
Breath CO and 
Tobacco Use and 
Beliefs on M/W/F 
($2) 
CDMI + CM Group: 
Same as above with 
payment contingent 
on breath CO/saliva 
cotinine level 
(plus $1) 
Control and CDMI 
Groups: 
Breath CO and 
Tobacco Use and 
Beliefs on M/W/F 
($2) 
CDMI + CM Group: 
Same as above with 
payment contingent 
on breath CO/saliva 
cotinine level 
(plus $1) 
Control and CDMI 
Groups: 
Breath CO and 
Tobacco Use and 
Beliefs on M/W/F 
($2) 
CDMI + CM Group: 
Same as above with 
payment contingent 












breath CO, saliva 
cotinine 
($15) 
< j j 
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APPENDIX H 
Details of Brief Computer-Delivered Motivational Intervention 
Introduction 
Hello, my name is Peedy. We will be working together today. 
If it's okay with you, I'd like to spend some time getting to know you better. 
Specifically, I'd like to learn a little bit more about your smoking and how you feel right 
now about quitting. 
You may know that smoking is bad for your health and that it can cause lung disease, 
stroke, cancer, and other health problems. Still, many people don't feel that they are ready 
to quit. We'll spend some time together today to try and understand how you feel about 
your smoking. I'm giving you no pressure to quit. I just met you. You know best what 
decision is the right one for you. Sometimes, though, people feel that they are really 
ready to quit smoking. If you are one of those people, one of the best things that you can 
do is to set a quit date. This is a day, usually within the next two weeks, that you choose 
to be the day that you stop smoking. Only you can choose what the best quit date for you 
may be. 
I'd like to check and see if you feel ready to set a quit date. Don't worry if you're not 
ready. Lots of people aren't. Remember, I don't want to pressure you in any way. I will 
respect anything that you decide. 
Do you feel ready right now to set a quit date? 
• Yes (on to "Setting a Quit Date") 
• No (on to "Pros and Cons") 
a I'm a little unsure (on to "Pros and Cons") 
Setting a Quit Date 
Sounds like you feel that the best thing for you is to set a quit date. There is a calendar 
next to the computer. Take a minute and choose which quit date you would like. 
Sometimes the best quit date is one that has a special meaning to you. 
What do you choose as your quit date to stop smoking? 
(Example) 
• Monday, July 30th 
a Tuesday, July 31st 
a Wednesday, August 1st 
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a Thursday, August 2nd 
a Friday, August 3rd 
• Saturday, August 4th 
a Sunday, August 5th 
• Monday, August 6th 
a Tuesday, August 7th 
a Wednesday, August 8th 
a Thursday, August 9th 
a Friday, August 10th 
a Saturday, August 11th 
a Sunday, August 12th 
a None of these dates 
(If a quit date is selected, Peedy reflects back the date that was chosen and the participant 
moves on to "Plan for Change". If "none of these dates" is selected, then the participant 
is taken to "Pros and Cons") 
Pros and Cons 
It sounds like you plan to keep smoking. At least for a while. I'm sure that you have your 
reasons for this. I definitely don't judge you for it and I won't try to force you to change. 
I'm just a fat green parrot anyway. 
But if it's OK, I'd like to talk with you just a little bit about what you're thinking right 
now. No pressure. I just want to help you think about what, if anything, you might want 
to change about your smoking. 
There can be lots of good and bad things about smoking. Let's think a bit about what 
those things are for you. 
Here are some positive things about smoking. I know there are lots of options. Take your 
time. I am only a bird. I don't have many important places that I need to be. 
What are some of the things you like about your smoking? 
(Participant chooses all that apply from the list below) 
a Smoking feels good 
a Smoking helps me relax and deal with stress 
a Smoking can be a good way to socialize and bond with other smokers 
• Smoking makes things more enjoyable 
a Smoking helps me lose weight or maintain my current weight 
a I like watching the smoke and the cigarette burn 
• Smoking keeps away withdrawals 
a I like taking smoke breaks throughout the day 
a Something else that is not on this list 
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a None of these options 
Now here are some negative things about smoking. I know I asked you some of these 
before, but I have a short memory. After all, my brain is only the size of a raisin. 
What are some of the things you don't like about your smoking? 
a Smoking costs a lot of money 
a Smoking affects my health and the functioning of my lungs 
a Smoking increases my risk of cancer and other diseases 
a I go through mini-withdrawals from nicotine throughout the day 
a I am afraid of what smoking is doing to my health or the health of those I love 
• Smoking makes my face and body look older 
a Not everyone in my family likes that I smoke 
a The smell of cigarettes gets in my clothes and hair 
a Something else that is not on this list 
a None of these options 
Sounds like you feel two ways about your smoking. On the one hand, you've told me that 
the good things about your smoking are that (Peedy reflects participant's selections) and 
maybe other positive things. But on the other hand, you also feel that the things you don't 
like about your smoking are (Peedy reflects participant's selections) and maybe other 
negative things. 
Everyone is different, but talking about the good and bad things about smoking can get 
people thinking. 
Overall, how would you rate the effect of smoking on your life? 
• It has no effect at all 
a It affects a few things 
a It affects a lot of things 
• It affects everything in my life 
(Participant moves on to "Feedback'') 
Feedback 
You told me before that you're not interested in changing, and I respect that. 
If you ever do start to think about changing though, there are some important things you 
might want to know about your smoking. 
Most people think this feedback is interesting. I will ask you later what you think of it. 
But whether you find it helpful or not, it's all just for you to consider. You can take or 
leave as much of it as you want. 
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I know I've asked you this before, you'll have to forgive me. There's that bird's memory 
again. 
























More than 40 
Depending on how much you smoke, cigarettes can cost a lot of money. 
How much do you think you spend on cigarettes per year? 







• $2000 or more 
By my estimate, based on the number of cigarettes you smoke each day and the cost of a 
pack of cigarettes, you actually spend {calculated amount based on number of cigarettes 
smoked per day) each year on cigarettes. Depending on what brand you smoke, it may 
cost you even more than this. 
That would buy me a lot of bird feed. 
What else could you do with the money you spend on cigarettes? 
• I could go on a vacation 
• I could use it to pay my bills 
p I could buy things for my children or grandchildren 
a I could buy myself some new clothes or other things that make me happy 
a I could buy a new car or start to save for one 
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• I could get a new TV or other electronics 
a I could save it for a rainy day 
a I could help out someone else financially 
• Some other reason not listed 
• None of these options 
Here's some trivia for you. 











Less than 5% 
5% to 10% 
10% to 20% 
20% to 30% 
30% to 40% 
40% to 50% 
50% to 60% 
60% to 70% 
70% to 80% 
80%) or more 
Based on the latest information that I have available to me, I can tell you that 21% of 
adult Americans smoke cigarettes. This means that 79% (or 4 out of 5) adults are non-
smokers. {Participant is shown a bar graph of number of smokers versus numbers of non-
smokers). 
As you can see from this chart, the number of smokers has been steadily declining over 
the past 50 years. {Participant is shown a graph demonstrating a decline in smoking rates 
over time). 
When we first started today, I asked you about some negative effects of your smoking. 
Let's talk about how your score on this questionnaire compares to others {referring to the 
Negative Effects of Smoking Questionnaire completed prior to the intervention). Relative 
to someone who experiences no negative effects from smoking and someone who 
experiences all the negative effects we talked about and gets the maximum score, this is 
where your score is. {Peedy demonstrates on a line where the participant's score fell 
relative to the minimum and maximum score). 
Now let's talk about your breath carbon monoxide (CO) reading. I will give you a little 
background on CO first. This is a poisonous gas that in large amounts can be fatal. 
Cigarettes produce CO and smokers often breathe in and out this dangerous gas. 










a 40 or higher 
The average breath carbon monoxide reading for non-smoking adults is around 2. The 
amount of carbon monoxide in your breath is (number of multiples higher than a non-
smoker, based on selected CO reading) that of a non-smoker. 
That's a lot of information and numbers that I just threw at you. Let's stop for a minute. 
I'm curious to know how you're feeling. 
What do you make of all that feedback? 
a I don't really care what feedback I get, it's not going to change me 
a I don't buy it. I know lots of people who smoke more than I do 
• I'm not sure I believe it 
• I don't smoke that much so it's no big deal 
• It's hard for me to have to face this 
a I'm shocked. I never knew these things about my smoking 
• I'm disappointed in myself 
a I'm feeling a way that's not on this list 
• I'm not feeling anything 
We've just talked a lot about your smoking. I know that you said earlier that you weren't 
ready to quit, but sometimes people start to feel a little bit differently. 
This little parrot is giving you no pressure to change. You can make your own decisions 
about what's best for you. I did want to check in though and see if you might have 
changed your mind since the last time I asked you. 
Are you thinking now that you'd like to set a quit date to stop smoking? 
a No (on to "What would make you decide to quit?") 
• Yes (on to ''Setting a Quit Date") 
a I'm going to keep thinking about it (on to "What would make you decide to 
quit?") 
Plan for Change 
Now that you have decided to stop smoking, let's spend a few minutes making a quit plan 
to ensure that you are as successful as possible. 
Before we start, there are some important things to know about change. First, change 
usually isn't easy. But, second, change can really happen. Most people who commit to 
change usually succeed. Third, if you decided you want to change, there are lots of ways 
to do it. You just have to find the one that's right for you. For example, getting help with 
quitting might be best for some people, but others might prefer to do it on their own. 
Fourth, many people who do quit slip a few times at first. They always learn from it. As 
long as you never give up, you never fail. 
I want to stop and check in with you. You've just told me that you want to quit smoking. 
This is a big decision, and it's normal to feel different ways about this. 
How are you feeling now that you've decided to quit smoking? 
a Scared 
• Motivated 




a Proud of myself 
• I'm not really sure yet 
• Something else not on this list 
• None of these options 
At this point, you might be wondering what you've gotten yourself into. You've told me 
that you want to quit, but let me check in with you and see if this is really what you want 
to do. 
What is the change that you want to make? 
a I want to stop smoking cigarettes completely 
• I want to cut down on the number of cigarettes I smoke 
Let's think about why you want to make this change. Everyone has different reasons, but 
let's find out what they are for you. 
Why do you want to quit smoking? 
• To improve my health 
• To live longer 
a To make my friends and family proud 
a Because I deserve to be a non-smoker 
• To save money 
a So people stop nagging me 
a I'm sick and tired of being a smoker 
a To stop or reverse what smoking has done to me physically 
a Something else not on this list 
a None of these options 
An important part of making a change is carefully planning out the steps you want to 
take. Everyone has a different plan for quitting. I will ask you about more possible steps 
in just a minute. 
What are the steps you will take in quitting? 
a I will throw out my cigarettes and lighters 
• I will distract myself when I have a craving for a cigarette 
• I will begin exercising more and drinking lots of water 
a I will keep track of each cigarette that I smoke 
• I will stay away from people who smoke or places where there is smoking 
a None of these options 
Here are some more steps to consider. 
What are the steps you plan to take in changing? 
a I will visit my doctor or talk with my counselor about my smoking 
a I will write down all the reasons why I want to quit 
• I will spend more of my time in places where smoking is not allowed 
• I will break my smoking habits, like having a cigarette when I wake up 
• I will use a nicotine patch or gum 
a I will do whatever comes naturally 
• Something else not on this list 
a None of these options 
Involving other people in your efforts to quit or cut back on smoking can be an important 
part of ensuring that you are successful. 
What are some of the ways that other people can help you quit smoking? 
a They can take my cigarettes from me 
a They can quit with me 
a They can encourage me to quit 
a They can ask how I am doing with quitting 
a They can support my efforts to quit 
a They can stop smoking around me 
a They can distract me when I have a craving 
a They can tell me how proud they are of me 
a Something else not on this list 
a None of these options 
You've taken the time to make a quit plan that is the best fit for you. An important part of 
making a plan like this is knowing when your plan is working. 
How will you know if your plan to quit smoking is working? 
a If I can go a full day or week without smoking 
• If I have fewer cravings for cigarettes 
a If I can cut the number of cigarettes I smoke in at least half 
• If I begin to feel like a non-smoker 
• If my breathing and lung functioning improves 
• If other people notice the changes I am making 
• If I can walk into a corner store and not buy cigarettes 
Q If I can refuse a cigarette that is offered to me 
a Something else not on this list 
a None of these options 
When you are making a change, it is also important to plan for things that could interfere 
with your goal to quit smoking. 
What are some things that could interfere with your goal to quit? 
a Being around people who smoke 
• If I am going through a very stressful time 
• If I find myself feeling depressed or nervous 
a If I talk myself out of quitting 
• If people pressure me to smoke 
a If I slip-up and have a cigarette 
a If I decide it's no longer important to quit 
a If I don't follow my change plan 
a Something else not on the list 
a None of the above 
Okay. You've just told me a lot of information about your plan to quit smoking. Birds like 
me don't have very big brains, so let's see if I've got all this straight. Your quit date is 
(Peedy reflects back participant's selections). You're feeling (Peedy reflects back 
participant's selections) and maybe some other feelings. All of these are normal reactions 
to such a big change. The change goal that you have set for yourself is (Peedy reflects 
back participant's selections). You've told me that the reasons you want to change are 
(Peedy reflects back participant's selections) and maybe some other reasons too. The 
steps you plan to take in changing are (Peedy reflects back participant's selections) or 
maybe something else that you feel will be helpful to you. 
You've also identified ways that people can help you make this change. You feel that 
others can help you by (Peedy reflects back participant's selections) and maybe by doing 
something else that you think would be useful to you. You've also shared with me ways 
that you will know when your plan is working. You will know if your plan to quit or cut 
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back on smoking is working if (Peedy reflects back participant's selections) or maybe 
something else. You also took the time to think about what might interfere with your plan 
to change. You feel that things that could interfere are (Peedy reflects back participant's 
selections) or maybe there is something else that could interfere with your goal. 
Before we finish up, I want to check in again and see how you're feeling. You came up 
with quite a plan for change, and I want to see what you think of it. 
How are you feeling after hearing your plan for change? 
• Eager to put my plan into action 
a Worried I can't do it 
• Excited to try it 
• Scared it will be hard 
a Doubting I can do this 
a It sounds overwhelming 
a I think it was helpful to have done this 
a Hopeful that this will work for me 
a Something else not on this list 
• None of these options 
(Participant proceeds to "Goodbye") 
What would make you decide to quit? 
I hear you telling me that you plan to keep on smoking. That's your decision to make, and 
I don't judge you for it. Thanks for being so honest with me. 
Before we finish, I'd like to find out what you feel might make you think more about 
quitting in the future. 
What would make you think more about quitting? 
a If I finally get tired of what smoking is doing to me 
a If my doctor tells me I have to 
• If someone I know gets sick or dies from smoking 
a If someone I care about asks me to quit 
• If I think more about the negative aspects of smoking 
• If I develop a health problem from smoking 
• I might just wake up one morning and decide to quit 
a Nothing could make me want to quit 
Q Something else not on the list 
• None of these options 
So you might consider quitting smoking (Peedy reflects back participant's selections) or 
maybe if something else happens in the future. Sounds like you know how important it 
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can be to keep an eye on your smoking and check in with yourself on whether you may 
want to quit. 
Goodbye 
Thank you for sharing your thoughts with me. That's all for today. 
Have a nice day! 
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APPENDIX I 
Details of Control Intervention 
Introduction 
Hello, my name is Peedy. We will be working together today. 
If it's okay with you, I'd like to spend some time today getting to know you better. 
Specifically, I will be asking you a little bit about your likes and dislikes when it comes 
to music and television. 
We'll also have the chance to watch some brief music videos and clips from television 
shows. 
I will begin by asking you some questions to learn more about your tastes in music. 
Here are some R & B artists. There definitely is a lot of talent amongst these musicians. 
Which of these artists do you like to listen to? 
• Aretha Franklin 
a Ray Charles 
• Stevie Wonder 
a Little Richard 
a The Supremes 
a Someone else not on this list 
a None of these options 
Now here are some rock artists. Some of these bands can really put on a good show. 





• Red Hot Chili Peppers 
a Someone else not on this list 
a None of these options 
Here are some heavy metal artists. You may or may not have heard of all of them. 
Which of these artists do you like to listen to? 
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• Metallica 
• Iron Maiden 
a Korn 
a Led Zeplin 
• ACDC 
• Someone else not on this list 
• None of these options 
Now here are some jazz musicians. I really enjoy listening to some good jazz music. 
Which of these artists do you like to listen to? 
a Diana Krall 
• Louis Armstrong 
• Nat King Cole 
a Miles Davis 
• Duke Ellington 
• Someone else not on this list 
• None of these options 
I hear you telling me that you like a lot of different musicians and types of music. So far 
you have said that you like (Peedy reflects back participant's selections) and maybe some 
other artists that weren't listed. 
Here are some rap artists. I like a lot of these guys but sometimes they use language that a 
bird like me can't handle. 
Which of these artists do you like to listen to? 
• Eminem 
• Snoop Dogg 
a 50 Cent 
• Diddy 
a JayZ 
a Someone else not on this list 
a None of these options 
Now here are some classical musicians. 






a Someone else not on this list 
a None of these options 
Here are some pop musicians or groups. I like to dance to this music sometimes. 
Which of these artists do you like to listen to? 
a Justin Timberlake 
a Britney Spears 
a Black Eyed Peas 
Q Madonna 
a Kelly Clarkson 
a Someone else not on this list 
a None of these options 
Here are some country musicians. I like this music, but sometimes the songs are kind of 
sad. 
Which of these artists do you like to listen to? 
• Kenny Chesney 
• Carrie Underwood 
• Johnny Cash 
a Tim McGraw 
a Garth Brooks 
a Someone else not on this list 
a None of these options 
You have told me that you like a lot of different types of music. You just said that you 
like (Peedy reflects back participant's selections) and maybe some other artists that 
weren't on the list of options. 
Now here's the fun part. I have some music clips for us to watch. 
Which one of these videos would you like to see? 
a Ring of Fire (Johnny Cash) 
• What a Wonderful World (Louis Armstrong) 
• Signed Sealed Delivered (Stevie Wonder and Beyonce) 
(Participant selects and watches a 2 minute video clip). 
That was good, wasn't it? 
Now let's talk about some television shows that you like. 
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First, I want to ask you a bit about how much television you watch. 
On average, how many hours of television do you watch each day? 
a I never watch television 
• Less than 30 minutes 
• 30 minutes -1 hour 
• 1-2 hours 
a 2-4 hours 
a 4-6 hours 
• 6-10 hours 
a More than 10 hours 
By my calculations, this means that you spend (number of hours based on participant's 
selection) hours per week, or (number of hours based on participant's selection) hours 
per year watching television. 
Do you ever wonder about how the amount of television you watch compares to others? 
How many hours a day do you think the average adult watches television? 
a Less than 30 minutes 
a 30 minutes to 1 hour 
a 1-2 hours 
a 2-4 hours 
a 4-6 hours 
• 6-10 hours 
a More than 10 hours 
According to the latest statistics, the average American adult watches four and a half 
hours of television a day. This equals sixteen hundred and forty two hours a year, or sixty 
eight full days. 
A few hours can really add up. I'm curious to know how you're feeling about the amount 
of television that you watch. 
Do you think you watch too much television? 
a No 
a Yes, I should really cut back 
a Yes, but I'm going to continue watching it as much as I do 
Now let's talk about what television shows you enjoy watching. 
Here are some reality television shows. 
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Which of these shows do you like to watch? 
• Survivor 
a Big Brother 
a America's Next Top Model 
a The Real World 
a American Idol 
a Something else not on the list 
a None of these options 
Here are some legal or crime shows. There sure are a lot of spin-offs of these shows, 
aren't there? 
Which of these shows do you enjoy watching? 
• Law and Order 
a Law and Order: SVU 
• CSI 
• CSI: Miami 
• CSI: New York 
a Something else not on this list 
a None of these options 
Now here are some game shows. Did you know that Bob Barker is retiring after hosting 
the Price is Right for 35 years? 
Which of these shows do you like to watch? 
• Jeopardy 
a Wheel of Fortune 
a Price is Right 
a Deal or No Deal 
a 1 vs. 100 
a Something else not on this list 
a None of these options 
I hear you telling me that you like watching a lot of different shows. So far you have said 
that you like (Peedy reflects back participant's selections) and maybe something else that 
was not on the list of options. 
Let's find out what other television shows you like. 
Here are some medical shows that are on television. Did you know that ER is now in its 
13th season? 
Which of these shows do you like to watch? 
• ER 




a Something else not on the list 
a None of these options 
Now here are some talk shows. Did you know that Oprah has signed on to do her show 
until two thousand and eleven? That will be 25 years on the air. 
Which of these shows do you like to watch? 
a Oprah 
• Tyra Banks 
• Maury Povich 
• Dr. Phil 
a Regis and Kelly 
• Something else not on the list 
• None of these options 
Here are some comedy shows. Some of these really make me laugh. 
Which of these shows do you like to watch? 
a Seinfeld 
a Fresh Prince of Bel-Air 
a Friends 
• Everybody Hates Chris 
• Family Guy 
a Something else not on the list 
a None of these options 
You have told me that you like different types of shows. You have said that you like 
(Peedy reflects back participant's selections) and maybe some other shows that weren't 
listed. 
The fun part again. I have a few clips from television shows that we can watch. 
Which one of these clips would you like to see? 
• Deal or No Deal 
a Seinfeld (Elaine Dancing) 
• Fresh Prince of Bel-Air (Carlton Dancing) 
(Participant selects and watches a 2 minute video clip). 
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Thank you for sharing your thoughts with me. That's all for today. 




1. Gender: Male Female 
2. Age: 
3. Ethnicity: African American Caucasian Other 
4. What is the highest level of education you have obtained? 
Less than High School (please indicate which grade: ) 
GED 
College/University 
5. Are you currently employed? Yes (Full time or Part time: ) 
No 
6. Please estimate your average income each month, from all sources: 




$2001 - $2500 
More than $2500 
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APPENDIX K 
Smoking Background Questionnaire 
1. How old were you when you smoked your first cigarette? 
2. How old were you when you started smoking regularly (three times a week or 
more)? 
3. How many YEARS in total would you say that you have smoked cigarettes? 
4. How many times in your life have you tried to quit smoking? 
5. What is the longest period of time that you have gone without smoking? 
6. Have you ever talked to your counsellor at the clinic about quitting smoking? 
7. How much money each WEEK do you generally spend on cigarettes? 
8. How many cigarettes do you generally smoke each day? 
9. What ways have you tried to quit smoking? (Check all that apply) 
• On my own ("cold-turkey") 
• Nicotine patches 
• Nicotine gum 
• Medication prescribed by a doctor (e.g., buproprion / Wellbutrin / Zyban) 





(Sobell & Sobell, 1996) 
Instructions: 
We would like you to recall what your cigarette use was like in the past 
month. This is not a difficult task when you use a calendar like the one below. As 
you can see, this calendar has important holidays marked on it. Take a moment 
to also write in your own personal holidays and events. These may include 
birthdays, trips, sporting events, or celebrations. 
Now, go through the calendar and write down how many cigarettes you 
smoked on each of the days. We want you to be as accurate as possible, 
although we know it is hard for anyone to recall things with 100% accuracy. You 
may also think about things like whether you tend to smoke more on the 
weekends, or if there were any days you didn't have cigarettes, went without 
them by choice, or if you were feeling sick and didn't smoke as much on certain 
days. 
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(Researcher marks the past 30 days on the calendar) 
JANUARY/FEBRUARY 



































































Brief Tobacco Quantity Assessment 
(Monday version) 
How many cigarettes did you smoke yesterday (Sunday)? 
How many cigarettes did you smoke the day before yesterday (Saturday)? 
How many cigarettes did you smoke three days ago (Friday)? 
(Wednesday version) 
How many cigarettes did you smoke yesterday (Tuesday)? 
How many cigarettes did you smoke the day before yesterday (Monday)? 
(Friday version) 
How many cigarettes did you smoke yesterday (Thursday)? 
How many cigarettes did you smoke the day before yesterday (Wednesday)? 
APPENDIX N 
Tobacco Use and Beliefs Measure 
How MOTIVATED are you to quit smoking? 
Not at all Extremely 
How CONFIDENT are you that you would be able to quit smoking 
if you wanted to? 
Not at all Extremely 
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APPENDIX O 
Fagerstrom Test for Nicotine Dependence 
(Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991) 
1. How soon after you wake up do you smoke your first cigarette? 
D After 60 minutes 
• 31-60 minutes 
• 6-30 minutes 
• Within 5 minutes 
2. Do you find it difficult to refrain from smoking in places where it is forbidden? 
D No 
D Yes 
3. Which cigarette would you hate most to give up? 
• The first in the morning 
• Any other 
4. How many cigarettes per day do you smoke? 
D 10 or less 
• 11-20 
• 21-30 
• 31 or more 
5. Do you smoke more frequently during the first hours after awakening than 








0-2 Very low dependence 
3-4 Low dependence 
5 Medium dependence 
6-7 High dependence 
8-10 Very high dependence 
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APPENDIX P 
Smoking Self-Efficacy Questionnaire-!2 (Etter, Bergman, Humair, & Perneger, 2000) 
The following are situations in which certain people 
might be tempted to smoke. Please indicate whether 
vou are sure vou could refrain from smokinq in each 
situation. 
1. When I feel nervous 
2. When I have a drink with friends 
3. When I feel depressed 
4. When celebrating something 
5. When I am angry 
6. When drinking wine, beer, or other spirits 
7. When I feel very anxious 
8. When I am with smokers 
9. When I want to think about a difficult problem 
10. After a meal 
11. When I feel the urge to smoke 






























































































Odd items: Internal stimuli subscale 
Even items: External stimuli subscale 
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APPENDIX Q 
Readiness to Change Questionnaire (Rollnick, Heather, Gold, & Hall, 1992) 
Below are a list of ways that people may feel 
about their smoking. Please circle the response 
that best suits you for each item. 
1.1 don't think I smoke too much (P) 
2. I am trying to smoke less than I used to (A) 
3.1 enjoy smoking but sometimes I smoke too much 
4. Sometimes I think I should cut down on my 
smoking (C) 
5. It's a waste of time thinking about my smoking (P) 
6. I have just recently changed my smoking habits 
(A) 
7. Anyone can talk about wanting to do something 
about smoking, but I am actually doing something 
8.1 am at the stage where I should think about 
smoking less (C) 
9. My smoking is a problem sometimes (C) 
10. There is no need for me to think about changing 
my smoking (P) 




















































































12. Smoking less cigarettes would be pointless for 
me(P) 
-2 -1 0 1 2 
Subscales: 
P = Precontemplation 
C = Contemplation 
A = Action 
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APPENDIX R 
Stage of Change Algorithm (DiClemente et al., 1991) 
Are you seriously thinking of quitting smoking? 
• Yes, within the next 30 days 
o If Yes: In the last year, how many times have you quit smoking for at least 
24 hours? (PREPARATION STAGE if they have one 24-hour quit attempt 
in the past year. If no quit attempt then CONTEMPLATION STAGE) 
• Yes, within the next 6 months (CONTEMPLATION STAGE) 
• No, not thinking of quitting (PRECONTEMPLATION STAGE) 
• I have already quit smoking (ACTION / MAINTENANCE) 
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APPENDIX S 
Negative Effects of Smoking Questionnaire 
Below are a list of negative effects smoking can have on 
someone. Please indicate to what extent each of these may 
have happened to you in the past 30 days. 
1.1 have been unhappy because of my cigarette smoking 
2.1 have felt guilty or ashamed because of my cigarette 
smoking 
3.1 feel out of breath if I walk up a flight of stairs 
4. My physical health has been harmed by cigarette smoking 
5.1 often have a cough that I can't get rid of 
6.1 worry that I am killing myself by smoking cigarettes 
7.1 am more at risk of developing lung, throat, or mouth 
cancer because of my cigarette smoking 
8.1 am more at risk of having a heart attack or stroke because 
of my cigarette smoking 
9.1 get very anxious, irritable, or moody when I can't have a 
cigarette 

































































11. My clothes, house, or car smell like cigarettes 
12. My physical appearance has been harmed by my smoking 
13. My breath often smells from smoking 
14. My fingers, teeth, or skin are yellow from smoking 
15. My skin is dry and my hair is brittle from smoking 
16.1 am fearful that the ones I love may be negatively affected 
by my cigarette smoking 
17. A friendship or close relationship has been damaged by 
my cigarette smoking 
18. My partner and I argue about my cigarette smoking 
19. My smoking has damaged my social life, popularity, or 
reputation 































Scoring = total on all items 
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APPENDIX T 
Attributes of Treatment Measure 
Be low are a list of ways people might feel about 
The treatment that they received in this study. 
Please circle the response that best suits you for 
each item. 
The treatment that 1 got... 
1. ...was helpful 
2. ...focused on things that were relevant to me 
3. ...was something that I would recommend 
4. ...didn't do much for me (R) 
5. ...was accepting 
6. ...made me want to change 
7. ...was understanding 
8. ...was respectful of me 
9. ...was unsupportive (R) 
10...was enjoyable 
11...was annoying (R) 
























































































R = reverse scored items 
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APPENDIX U 
Motivation for Change Questionnaire 
Be low are a list of reasons that people may give 
for changing or trying to change their smoking 
behaviour. Please think about how each reason 
fits for you during your participation in this study 
and circle the best response. 
1. I didn't have any choice (E) 
2. I got paid for doing it (E) 
3. It is something I was interested in doing (I) 
4. It is good for my health (I) 
5. I was supposed to do it (E) 
6.1 wanted to do it for myself (I) 
7.1 didn't want to disappoint the researcher (E) 
8. It made me feel good about myself (I) 
9.1 knew I was being monitored (E) 














































































E =External motivation subscale 
I = Internal motivation subscale 
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APPENDIX V 
Treatment Self-Regulation Questionnaire (Williams, Freedman, & Deci, 1998) 
The following questions relate to the 
reasons why you might have tried to quit 
or cut back on smoking over the course 
of this study. Different people have 
different reasons for doing that, and we 
want to know how true each of the 
following reasons are for you 
The reason I tried to quit or cut back on 
Smoking is... 
1. Because I felt I wanted to take 
responsibility for my own health (A) 
2. Because I felt guilty or ashamed of 
myself (C) 
3. Because I personally believed it was 
the best thing for my health (A) 
4. Because others would be upset with 
me if I smoked (C) 
5. I really didn't think about it (AM) 
6. Because I thought carefully about it 
and believe it is very important for 
many aspects of my health (A) 
7. Because I would have felt bad about 












































































The reason 1 tried to cut or quit back on 
smoking is... 
8. Because it is an important choice 1 
really wanted to make (A) 
9. Because it was easier to do what 1 am 
told than to think about it (C) 
10. Because I felt pressure from others not 
to smoke (AM) 
11. Because it was consistent with my life 
goals (A) 
12. Because I wanted others to approve of 
(C) 
13. Because it was very important for being 
healthy as possible (A) 
14. Because I wanted others to see that I 
could do it (C) 


















































































A = Autonomous response items 
C = Controlled response items 
AM = Amotivational response items 
APPENDIX W 
Additional Analysis of Breath CO Results 
Consecutive breath CO samples in non-smoker range 
The number of consecutive days breath CO was in the non-smoking range was 
compared (Figure 13). Statistical analysis of these data (a univariate ANCOVA with 
number of samples in the non-smoker range during the baseline week as the covariate) 
revealed a significant difference between the groups, F(2,33) = 3.94,p = .03, n p =.19. 
Further analysis (Fisher's LSD post-hocs) indicated that the CDMI plus CM group had 
significantly more non-smoking days in a row than the control group (Mean Difference = 
.25, p = .01). The number of consecutive non-smoking days by the CDMI only group did 
not significantly differ from the control (Mean Difference = .11,/? = .20) or the CDMI 
plus CM group (Mean Difference = -.14, p = .13). 
Two group comparisons were run and partial eta-squared was used to calculate 
Cohen's d. These results revealed a large advantage for CDMI only (d= 1.13) and CDMI 
plus CM (d=l.\0) over the control group. A moderate effect for the magnitude of the 
difference between CDMI only and CDMI plus CM was also found (d = .52), with the 
CDMI plus CM group producing more consecutive days in the non-smoking range. 
Breath CO reductions of 25% relative to baseline 
An analysis was done on the number of breath CO samples reduced 25% relative 
to baseline (Figure 14). A statistical analysis of these data (a univariate ANOVA) 
indicated a significant difference between the groups, F(2,34) = 3.63,/? = .04, r|2p =.18. 









Control CDMI only CDMI plus CM 
Figure 13. Number of consecutive breath CO samples in the non-smoker range across 
the study period. 
significantly more days where breath CO was reduced by 25% than the control group 
(Mean Difference = -3.54, p = .01). The difference between the CDMI only and CDMI 
plus CM group was a non- significant trend (Mean Difference = 1.44, p = .07). No 
significant difference was found between the control and CDMI only group (Mean 
Difference = . 83, p = . 55). 
Effect size estimates revealed a large magnitude of effect when CDMI plus CM 
was compared to control (d = 1.08) and CDMI only (d = .89), with the CM group 
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Control CDMI only CDMI plus CM 
Figure 14. Number of days during the study period that breath CO was reduced by 25% 
relative to baseline. 
effect was found between the control and CDMI only group (d = .54), with the control 
group producing the fewest number of samples that met this criterion. 
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APPENDIX X 
Results for Fagerstrom Test for Nicotine Dependence 
Overall Fagerstrom scores for all participants were in the low to moderate range 
of nicotine dependence. These scores showed some small variations from baseline to 
post-study. At follow-up, the Fagerstrom scores had increased to at or above baseline 
values for the CDMI only and control group (Figure 15). The CDMI plus CM group 
showed a small decrease relative to both baseline and post-study. 
Summary of Fagerstrom findings 
These results suggest that there was no difference in Fagerstrom scores between 
the groups, either at post-study or follow-up. 
Baseline versus post-treatment 
Change scores (post-study minus baseline scores) were essentially the same 
across the three groups, F(2,34) = .04, p = .96, \]2P =.00. 
Baseline versus follow-up 
Fagerstrom scores at follow-up were also compared (controlling for baseline 
scores). No significant difference was found between the groups, F(2,33) = .17, p = .47, 
n2P=.04. 
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Results for Smoking Self-Efficacy Questionnaire-12 
Internal subscale 
Across all participants, the internal motivation subscale scores were in the low to 
moderate possible range of scores for this measure. Overall internal subscale scores for 
all participants showed a small increase between baseline and post-study. This increase 
was maintained at follow-up. When the groups were examined separately, only the CDMI 
only group showed a steady increase in internal self-efficacy across post-study and 
follow-up (Figure 16). The other two groups were highest at post-study and decreased at 
follow-up. 
Summary of internal subscale findings 
These results indicate that there were no significant differences between the 
groups on the internal subscale scores, either at post-study or follow-up. 
Baseline versus post-study 
Change scores were calculated for each of the groups on the post-study internal 
subscale values, taking into account baseline values. No significant differences were 
found, F(2,34) = .16,p = .85, r|2p = 01. 
Baseline versus follow-up 
Similar scores were calculated for the follow-up values, controlling for baseline 











- • - Control 
-•-CDMIonly 
-A-CDMIplusCM 
Baseline Post-study Follow-up 
Figure 16. Smoking Self-Efficacy Internal Subscale scores across baseline, post-study 
and follow-up. 
External subscale 
The external scores were in the low to moderate range and remained relatively 
constant across time for all three groups across post-study and follow-up (Figure 17). 
Summary of external subscale findings 
These results indicate that there were no significant differences between the 










Baseline Post-study Follow-up 
Figure 17. Smoking Self-Efficacy External Subscale scores across baseline, post-study 
and follow-up. 
Baseline versus post-study 
Statistical analysis of the post-study external subscale scores (minus baseline 
scores) showed that the level of change across the three groups did not differ, F(2,34) = 
.05,/?=.95,r|2p = 00. 
Baseline versus follow-up 
Similarly, no difference was found on follow-up scores (controlling for baseline 
values), F(2,33) = .05,/? = .95, n2p =.00. 
APPENDIX Z 
Results for Readiness to Change Questionnaire 
An analysis of the Readiness to Change stage scores across all participants 
showed that at baseline, post-study, and follow-up, approximately two thirds of the 
participants were in the contemplation stage of change (Table 7). This suggests that 
throughout the study, the majority of participants were considering making a change in 
their smoking but had not yet progressed to the action stage. The percentage of 
participants in the preparation stage of change appeared particularly stable for the 
combined intervention group, CDMI plus CM, while the other two groups showed a 
slightly larger degree of progression through the stages of change. 
There were no statistically significant group differences in stage of change at 
baseline, %2(4) = 4.90,p = .30; post-study, x2(4) = 1.49,/? = .83; or follow-up, ^(6) = 
6.42,/? = .38. 
Table 7 
Percentage of participants in each stage of change (Readiness to Change Questionnaire 
scores) 










































Results for Stages of Change Algorithm 
Across all three groups, approximately three quarters of participants were in the 
contemplation stage at baseline. At post-study and follow-up, approximately half of the 
participants remained in the contemplation stage, while one third to one quarter had 
progressed to the preparation stage of change (Table 8). 
There were no group differences in stage of change at baseline, %2(4) = 2.10, p = 
.72; post-study, tf(6) = 6.42, p = .38; or follow-up, x2(4) = .97, p = .92. 
Table 8 
Percentage of participants in each stage of change (Stages of Change Algorithm) 










































Results for Illicit Drug Use 
Urine drug information from each of the participants was recorded for the period 
five weeks prior to the study (pre-study), the four weeks of the study period plus baseline 
week (study period), and the five weeks between the end of the study period and follow-
up (post-study). These drug screens were provided randomly as part of regular clinic 
procedures; therefore the number of drug screens was different for each participant. To 
ensure these comparisons were equivalent, the percentage of positive screens of those 
provided during each of these time points was calculated for each participant. 
Opiates 
Across all participants, rates of illicit opiate use were relatively moderate (average 
of 43.2% pre-study and 32.2% at post-study). This use progressively decreased from pre-
study, to study period, to post-study. Looking at each group separately, each of the three 
groups decreased their opiate use during the study period relative to pre-study (Figure 
18). The CDMI and CDMI plus CM groups continued this reduction to post-study, while 
opiate use increased (although not to baseline levels) for the control group at follow-up. 
Summary of findings for opiate use 
No differences were found between the groups on opiate use during the study 












Pre-study Study Period Post-study 
Figure 18. Percentage of opiate positive urine drug screens across the 5-weeks pre-study, 
the 5-week study period, and 5-weeks post-study. 
Study period versus pre-study 
In order to calculate Cohen's d as a measure of effect size, change scores were 
calculated for the percentage of urine drug screens positive for opiates during the study, 
minus the percentage that were positive prior to the study. These scores were not 
significant with a univariate ANOVA, F(2,29) = .33,p = .72, r\\ =.02. 
Post-study versus pre-study 
Change scores for opiate use at post-study (minus baseline use), did not show 
differential reductions between the three groups, F(2,28) = .18,/? = .84, n2p =.01. 
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Cocaine 
Overall rates of cocaine use were relatively moderate (34.8% at pre-study and 
26.9% at post-study). The overall rate of cocaine use across the three groups showed a 
reduction across the three time points. Control participants maintained their rate of use 
from pre-study through the study period, and then increased their use post-study (Figure 
19). The two groups that received the CDMI showed reductions in cocaine use across 
each of the three time points. This reduction was most apparent for the combined CDMI 
and CM group, who reduced their cocaine use by more than half from pre-study to post-
study. 
Summary of results for cocaine use 
Effect size estimates suggest that CDMI plus CM was the most efficacious in 
producing reduced levels of cocaine use post-study, relative to pre-study. No differences 
between the groups were found during the study period, relative to pre-study. 
Study period versus pre-study 
Rates of cocaine use during the study period (minus pre-study rates of use) were 
compared and no significant difference between the groups was found, F(2,28) = .72, p = 









Pre-study Study Period Post-study 
- • - Control 
-»-CDMI only 
-*-CDMI plus CM 
Figure 19. Percentage of cocaine positive urine drug screens across the 5-weeks pre-
study, the 5-week study period, and 5-weeks post-study. 
Post-study versus pre-study 
A comparison of the change scores from pre-study to post-study found a non-
significant trend (p < .30) in the difference between the groups, F(2,27) = 1.89,/? = .17, 
r)2p =.12. Effect sizes revealed that relative to the control group (which increased their 
rates of cocaine use over this time), the CDMI only group showed a moderate advantage 
in reducing cocaine use (d = .53), while this advantage was large for the CDMI plus CM 
(d= .81). The combined intervention of CDMI plus CM showed a small to moderate 
magnitude of effect size over CDMI only (d= .35). 
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APPENDIX AC 
Notable Participant Characteristics 
It was initially desired to examine the effect of ethnicity on study variables, as 
previous work has found larger effects of MI on minority participants relative to 
Caucasian samples (Hettema et al., 2005). Due to the low number of Caucasian 
participants in our study sample (N = 4), these analyses could not be done. Further 
complicating this was the fact that all four Caucasian participants were female, and all 
had recently given birth or gave birth during the study period (as this particular clinic was 
running a program for pregnant women on methadone). One additional African American 
woman was also a new mother. Research has shown that it is particularly hard to affect 
substance use-related change in pregnant and post-partum women who continue to use 
during their pregnancy (e.g., Ondersma et al., 2005; Ondersma et al., 2007). This is 
primarily due to the fact that women who do not quit smoking or using drugs when they 
first become pregnant are not likely to quit during the pre- and post-partum period. 
While analysis of these factors is beyond the scope of this dissertation, informal 
comparisons between these Caucasian mothers and African American participants across 
all three study groups reveals a very interesting pattern of results. While the Caucasian 
mothers demonstrated higher (and increased over time) levels of breath CO, saliva 
cotinine, and self-reported number of cigarettes relative to African American participants, 
their self-reported level of motivation was much higher. Therefore, while their motivation 
was high, their efficacy to stop smoking was low. Their overall acceptability of the 
interventions offered to them in this study (as measured by the Attributes of Treatment 
Measure), while still relatively high, was also significantly lower (M= 3.45, SD = .39) 
than that of African American participants (M= 3.99, SD = .36), F(l,32) = 7.51,;? = .01, 
n2 p=19. 
It is not known whether these observed differences are due to effects of ethnicity, 
pre- and post-natal factors, or even gender. This is an interesting area of investigation, 
and future research with adequate sample sizes is needed to tease apart these effects. 
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